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RESUMO 
 
ACESSO A MEDICAMENTOS ESSENCIAIS EM TIMOR-LESTE: 
DISPONIBILIDADE, PREÇOS E CAPACIDADE DE AQUISIÇÃO 
MARIANA REIS PINTO 
 
PALAVRAS-CHAVE: disponibilidade de medicamentos, preços de medicamentos, 
capacidade de aquisição de medicamentos, regulamentação do sector farmacêutico 
em países de médios e baixos rendimentos, medicamentos em Timor-Leste. 
 
O acesso a medicamentos essenciais a preços acessíveis de forma sustentável é um 
dos indicadores do cumprimento dos Objectivos de Desenvolvimento do Milénio e 
pode ser considerado como parte do direito universal à saúde. Tal como acontece 
com outros bens essenciais, o acesso aos medicamentos depende de múltiplos 
factores, como a sua disponibilidade, preços e capacidade de aquisição por parte da 
população. Na última década, foram efectuados mais de 50 estudos para avaliar esses 
factores, em países de baixos e médios rendimentos, utilizando uma metodologia 
desenvolvida pela Organização Mundial de Saúde e a organização Health Action 
International, numa tentativa de compreender as possíveis causas para o baixo 
acesso aos medicamentos. Os resultados destes estudos revelam uma baixa 
disponibilidade de medicamentos essenciais de um modo geral, sobretudo no sector 
público, e preços elevados, sobretudo no sector privado. 
O objectivo deste estudo foi descrever a disponibilidade, os preços e a capacidade de 
aquisição de medicamentos essenciais em Timor-Leste, com recurso à metodologia 
da OMS/HAI. Foram recolhidos dados sobre a disponibilidade e os preços de uma 
lista de medicamentos em hospitais, centros de saúde e farmácias comunitárias.  
Embora os resultados pareçam apontar para uma disponibilidade global razoável de 
medicamentos genéricos no sector público (59,2%), algumas substâncias activas e 
classes terapêuticas encontravam-se sistematicamente esgotadas em vários pontos do 
país. Nas unidades situadas em locais mais remotos, a disponibilidade de 
medicamentos chegava a descer para valores na ordem dos 47,5%. Verificou-se que a 
disponibilidade de medicamentos nas farmácias privadas era ainda mais baixa do que 
nos serviços públicos (38,0%). Os medicamentos são dispensados gratuitamente nos 
hospitais e centros de saúde, mas nas farmácias privadas chegam a ultrapassar 40 
vezes os seus preços de referência internacionais, mesmo como genéricos. 
Consequentemente, estima-se por exemplo, que um funcionário público que utilize 
diclofenac para o tratamento crónico da artrose, tenha de trabalhar durante mais de 2 
dias para pagar o seu tratamento mensal com o medicamento genérico, ou 12,5 dias, 
se for prescrito o medicamento de marca. Durante o estudo, foram detectados vários 
outros problemas que podem comprometer a qualidade e segurança dos 
medicamentos. 
Apesar das limitações inerentes a uma investigação deste tipo, foi possível concluir 
através do presente estudo que, ao contrário da tendência geral observada em países 
similares, o sector público de cuidados de saúde em Timor-Leste parece ter um 
melhor desempenho do que o privado. No entanto, as condições limitadas da maioria 
das unidades de saúde públicas pode forçar alguns doentes a recorrer ao sector 
privado, onde os preços pagos pelos tratamentos são inaceitavelmente elevados. A 
ausência de regulamentação do sector farmacêutico (e fiscalização insuficiente da 
existente) parece estar a contribuir para a estagnação do sector privado e a encorajar 
indirectamente a falta de transparência nas práticas farmacêuticas.   
Dada a escassez de estudos sobre este assunto em Timor-Leste, espera-se que o 
presente trabalho forneça evidências importantes que possam ser utilizadas em 
estudos subsequentes e como base a uma intervenção por parte das autoridades com 
o objectivo de melhorar a disponibilidade de medicamentos no sistema público e de 
encorajar o desenvolvimento do sector privado como alternativa viável, segura e de 
custo aceitável.  
  
 
  
	    
ABSTRACT 
 
ACCESS TO ESSENTIAL MEDICINES IN TIMOR-LESTE: AVAILABILITY, 
PRICES AND AFFORDABILITY 
MARIANA REIS PINTO 
 
KEYWORDS: drugs availability, drugs prices, affordability of medicines, access to 
medicines, pharmaceutical regulation in low- and middle-income countries, medicines in 
Timor-Leste. 
 
Access to affordable essential medicines on a sustainable basis is one of the 
indicators of compliance with the Millennium Development Goals, and can be 
regarded as part of the human universal right to health. As with other basic 
commodities, access to medicines depends on multiple factors, like their availability, 
prices and affordability. Over the last decade, more than 50 surveys using a 
methodology developed by the World Health Organization and Health Action 
International have been carried out in low- and middle-income countries, to assess 
these parameters in an attempt to understand the causes underlying poor access to 
medicines. Findings typically reveal low availability of essential medicines, 
particularly in the public health system, and high prices, especially in the private for-
profit sector. 
The objective of the present study was to describe the availability, prices and 
affordability of essential medicines in Timor-Leste using the WHO/HAI 
methodology. Data on the availability and prices of a drug tracer list was collected 
from a sample of hospitals, community health centres and private retail pharmacies.  
Although results seem to show a reasonable overall availability of generic medicines 
in the public sector (59.2%), some active substances and therapeutic classes were 
found to be consistently out of stock across the country. In facilities located in more 
remote areas, availability could be as low as 47.5%. Drug availability in private 
pharmacies was found to be even lower (38.0%). Medicines are dispensed free of 
charge in public health facilities, but in private pharmacies they were found to cost 
up to 40 times their international reference price, even as generics. As a result, it is 
estimated that a common government worker using diclofenac to treat chronic 
arthritis, for instance, would have to work 2.3 days to pay for his monthly treatment 
with the generic drug, or 12.5 days if the originator brand was prescribed. Other 
problems affecting medicines quality and safety were also detected throughout the 
study. 
Despite its limitations, the present study concluded that, contrarily to the general 
trend observed in similar countries, the public healthcare system in Timor-Leste 
seems to perform better than private. Nevertheless, the far from ideal conditions of 
most public health facilities can still push some patients to the private sector where 
costs of treatment are unacceptably high. The lack of regulation of the 
pharmaceutical sector (and inefficient monitoring/inspection of the existing one) 
seems to be contributing to the private sector’s stagnation and indirectly encouraging 
lack of transparency in pharmacy practice.   
Given the paucity of studies on the subject in Timor-Leste, it is hoped that the 
present work will provide an important evidence base for subsequent studies, and 
government intervention to better regulate the pharmaceutical sector, with the 
ultimate objective to improve the public drug supply, and encourage the growth of 
the private sector as a viable, affordable and safe alternative.  
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INTRODUCTION 
Access to medicines is widely recognised as a critical factor in ensuring people 
right to health. However, one third of the world’s population still lack sustainable 
access to essential medicines. Medicines availability and prices, both in the public and 
private sectors, are often considered proxies for access to markets and to 
pharmacological treatment in low and middle-income settings. The patterns identified 
are generally comparable across the countries analysed, where low availability 
(particularly acute in the public sector) and selling prices that largely exceed their 
respective international reference price are often reported. Low availability in the public 
sector forces patients to use the private sector, where prices are typically much higher. 
As medicines are normally purchased through out-of-pocket expenses in low and 
middle-income countries, excessive prices make them highly unaffordable to large 
sections of the population.  
The objective of this research is to explore the access of the population of 
Timor-Leste to essential medicines, in public or private sectors, and to analyze the 
impact a pharmacological treatment might have on household expenses. This study is 
based on the standard methodology for measuring drug prices and availability 
developed by the World Health Organization (WHO) in collaboration with the non-
governmental organization Health Action International (HAI).  
The structure of this thesis is as follows: 
• Chapter 1: Literature review, which is divided in three parts: the first reviewing 
the existing body of knowledge around access to essential medicines; the second 
is a country overview, focusing on the structure of the national health system 
and pharmaceutical sector in Timor-Leste; finally, the last part describes the 
objectives of the present study; 
• Chapter 2: Methods, data collection and data analysis; description of the 
WHO/HAI approach, and its application to the present research; 
• Chapter 3: results obtained with this research; 
• Chapter 4: Discussion of results, study limitations, policy implications, 
recommendations for future research areas and conclusions.  
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1. LITERATURE REVIEW 
1.1. ACCESS TO ESSENTIAL MEDICINES 
Having access to medicines has long been recognised as a critical factor in 
ensuring people’s health.(1) Providing access to affordable essential drugs on a 
sustainable basis in developing countries is one of the targets included in one of the 
Millennium Development Goals1 (MDG 8, target 8.E).(2) However, one third of the 
world’s populations still lack sustainable access to essential medicines.(3) Essential 
medicines represent a crucial element for interventions aimed to achieve other 
Millennium Development Goals, such as MDG 4 (reduce child mortality), MDG 5 
(improve maternal health) and MDG 6 (combat HIV/AIDS, malaria and other 
diseases).(4) 
Access has been defined as a ‘general concept that summarizes a set of more 
specific dimensions describing the fit between the patient and the health care 
system’.(5) In fact, the term ‘access’ brings together several factors, which can include 
the population’s care-seeking patterns, the location of facilities dispensing medicines 
and transport conditions within the country or region, availability of medicines at point 
of care and the population’s ability to pay for medicines. Some dimensions of access 
have been identified as particularly relevant in the case of medicines and other health 
commodities: physical availability, affordability (or ability to pay), geographical 
accessibility and acceptability (or satisfaction).(6) The World Health Organization 
(WHO) also defines access to essential medicines from the patient’s point of view as a 
situation when ‘drugs can be obtained within reasonable travelling distance (i.e. are 
geographically accessible), they are readily available in health facilities (i.e. are 
physically available), and affordable (i.e. are financially available)’.(7) 
Although each one of these dimensions can be explored through a set of 
indicators, medicine’s availability, prices and treatment affordability have been used as 
proxies for access to medicines in low and middle-income settings and several studies 
have been conducted using these two dimensions of access. The patterns identified are 
generally comparable across the countries analysed to date, where low availability 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1In 2000, 189 nations undersigned a promise to free people from extreme poverty and deprivations 
worldwide by 2015. This pledge – the United Nation’s Millennium Declaration – was converted into the 
eight Millennium Development Goals.	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(especially marked in the public sector) and high prices are often reported when 
compared to international reference prices.(8) As medicines in the private sector are 
normally purchased through out-of-pocket expenses in low and middle-income 
countries, high market prices make them highly unaffordable to large sections of the 
population, preventing individuals from accessing treatment in contexts where they 
cannot rely on the public health system for medicines. The situation is even more 
dramatic when chronic diseases, requiring long-term treatments, are considered.(8, 9) 
This chapter describes the two dimensions of access commonly used to estimate 
the overall access to essential medicines – availability and affordability (through the 
analysis of prices), using one particular tool that has been especially developed for this 
kind of analysis. 
 
1.1.1. Availability of medicines 
The consultative meeting held between WHO and the non-profit international 
health organization Management Sciences for Health (MSH) to define the concept of 
access and its dimensions, refers to physical availability as ‘the relationship between the 
type and quantity of product or service needed, and the type and quantity of product or 
service provided’.(6) 
Availability of essential medicines directly influences the capacity of the 
healthcare facility to immediately respond to patient’s needs, but also indirectly, since 
confidence in the healthcare system depends on having resources to ensure care is 
provided when needed. The availability of essential medicines influences the health-
seeking patterns of the population, encouraging them to use healthcare facilities if they 
know they can be adequately treated and/or benefit from preventive services and other 
health interventions. If drugs are constantly out of stock, attendance tends to be 
lower.(7) 
Availability of (good-quality) essential medicines depends on an efficient supply 
system, which includes factors such as the selection, procurement and distribution of 
drugs. Availability is also influenced by the prescription and utilization patterns of 
healthcare personnel, and an adequate coordination between these two dimensions 
(supply and use) is a critical factor in healthcare provision at point of care.(3) 
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In some contexts, drug donations can also have an important role on the 
availability of medicines, but over the years many problems arose around this issue, 
which led WHO to release in 1996 a document of Guidelines for Drug Donations aimed 
to improve the quality of drug donations.(10) Despite the important contribution of this 
document there is still some evidence of inappropriate practices in some countries. An 
adequate communication system between donors and recipients has been identified as a 
crucial factor to ensure drug donations follow WHO’s guidelines.(11) 
 
Although different methods of measuring availability emerged in the past, one of 
the most common practices is to define availability as “the number of medicines – from 
a pre-defined list of indicator medicines – available across a set number of selected sites, 
summarised as a percentage”.(12) Medicines physical existence can be measured on site 
over a pre-defined period of time or on a specific date of visit. This kind of approach to 
measure of availability has been used in a wide range of recent studies.(8) 
 
1.1.2. Medicines prices 
Public policies on medicine distribution to the population vary among countries. 
In some countries, people pay for medicines provided by the national health system, 
although in many cases some groups are exempt (children, pregnant women, elderly). In 
other cases only a prescription fee exists or part of the costs are supported by the state. 
There are also countries where medicines in public health services are distributed free of 
charge, with no additional costs imposed by the health system.(8)  
However, several surveys conducted in low-income countries over the last years 
consistently show a lack of availability of medicines in the public sector (3,9,13) 
forcing patients to search for their medicines elsewhere, in the private sector. However, 
the private sector is not always well regulated in these countries, and some availability 
problems also arise at this level. Additionally, even when medicines are actually 
available in the private pharmacies, prices are often very high, making them 
unaffordable for the most deprived population groups.  
Several components can contribute to the final price of a medicine. These 
components correspond to the respective mark-ups applied to the baseline price of a 
medicine (MSP, or manufacturer’s selling price) by the various market players along its 
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supply chain. These components can include freight or insurance costs, import taxes, 
port fees, margins applied by importers, wholesalers and retail distributors, as well as 
dispensing fees or other applicable fees. Depending on the market structure, these mark-
ups typically range from 30 to 45% of the final price of the medicine, but can exceed 
100%, depending on the pharmaceutical sector’s regulation.(14) 
Medicines price is a key factor for access to treatment. In 1986, the international 
organization MSH launched the annual publication International Drug Price Indicator 
Guide;(15) since 2000, WHO collaborates in its edition. The guide lists medicines 
supplier and buyer (tender) prices and estimates a median price based on the suppliers’ 
prices to be used as the international reference price (IRP). The tender price is used for 
products that have no supplier price.(14) The objective of the price guide is to make 
information on drug prices widely available to help improving the procurement of 
medicines, since great variations can occur according to the procurement methods used 
or the negotiation capacity of the entity responsible for the procurement process. Price 
information is therefore crucial to ensure the efficiency of local procurement systems. 
Medicine prices have been collected in several surveys at national and regional 
levels. This type of analysis can focus on lists of essential medicines or on specific 
groups of medicines, such as cardiovascular therapy or reproductive health. Given the 
importance of generic medicines on equitable access to treatments, data is usually 
collected not only for originator brands but also for the generic equivalent of the same 
active substance. Recent data from a pooled analysis of worldwide price surveys 
indicate prices at least 10 times higher for originator brands and at least 2.6 higher for 
lowest-priced generics, with marked variations across world regions.(8) 
 
1.1.3. Affordability of treatments 
Medicines are estimated to represent 20-60% of all expenses related to health in 
low-income countries (3) and part of treatment costs are directly supported by patients 
(through direct or out-of-pocket payments).(16) For this reason, WHO has considered 
“affordable prices” as one of the four key factors on which access to medicines depends, 
along with rational selection and use of medicines, sustainable financing and reliable 
health and supply systems.(17) 
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Affordability is, however, a broad and vague concept, which depends to a great 
extent on the commodity it relates to.(18) Operationalizing the affordability concept in 
the field of medicines was therefore considered important to gain some insight into the 
impact of such commodities in household expenses and some attempts have been made 
to identify the best approach to measure it.  
WHO and MSH considers affordability of medicines and other health 
commodities ‘defined by the relationship between prices of the products or services and 
the user’s ability to pay for them’.(6) A list of indicators was developed to measure this 
relationship, including direct comparisons to international prices and the number of 
days lowest-paid government employee must work to pay for a standard recommended 
course of therapy for tracer conditions; this last approach has been used in many studies 
over the recent years. It consists of converting the price of one course of treatment into 
working days (i.e. the equivalent daily wage) of the lowest paid unskilled government 
worker. A course of treatment for a given condition is considered affordable if its price 
does not exceed the equivalent to one daily wage; treatments that go over this threshold 
are considered unaffordable.(8) This method is sometimes criticised when applied to 
low-income countries (18,19) since it is estimated that large sections of the population 
earn much less than the lowest paid unskilled government worker. 
Some authors have suggested other different approaches to measure affordability 
applied to medicines.(18) Two alternative methods include the catastrophic impact of 
expenditures on medicines (which calculates the amount spent on medicines as a 
proportion of the household expenditures, classifying them as ‘catastrophic’ if they 
exceed a certain proportion) and the impoverishing effect of expenditures on medicines 
(which measures the percentage of the population that would be pushed below the 
poverty threshold – USD 1.25 or 2.00/day – after purchasing treatment).(20) 
Nevertheless, none of the mentioned approaches takes into account other 
expenses related to seeking pharmacological treatment. The price of medicines alone 
doesn’t fully reflect the costs associated to the treatment of a certain health condition, 
since other costs (such as transport to the point of care, doctor’s fees, loss of working 
time for the individual and caretaker, among others), can impose additional 
expenses.(20) However, since the price of medicines normally represents an important 
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share of the overall cost of treatment, it is frequently used as a reasonable estimate of 
the affordability of treatments. 
 
1.1.4. Measuring the access to essential medicines 
Acknowledging the impact that medicines availability and prices have in the 
access of the population to adequate medical treatment, several civil society 
organizations started to carry out a few small-scale studies in developing countries to 
measure medicine prices and make international comparisons in the mid-90s. However, 
methodological discrepancies made comparisons between countries difficult.(14) In 
2001, the World Health Assembly highlighted the importance of monitoring medicines 
availability and prices with the ultimate goal of overcoming inequities on the access to 
essential medicines.(21) 
The need to collect consistent data on medicines availability and prices in 
different settings, allowing international and cross-country comparisons, was therefore 
recognised, leading to the development of a standard methodology through a 
collaborative project between WHO and Health Action International (Project on 
Medicine Prices and Availability, hereinafter referred to as WHO/HAI project or 
WHO/HAI methodology). The aim of this project was to consistently collect and 
analyse data on medicines availability and prices in order to produce reliable and 
comparable information that could be subsequently used as guidance by policy makers 
and other stakeholders in the health and pharmaceutical sectors to improve access to 
affordable medicines, especially in low- and middle-income countries.(14) 
The methodology was launched at the 2003 World Health Assembly as a draft 
after which studies were undertaken to validate the sampling methodology and the price 
collection component. The results confirmed the appropriateness of the WHO/HAI 
approach.(14, 22) 
To date, WHO/HAI methodology has already been used in several national and 
regional studies,(23-25) and can be adapted to focus on particular intervention areas or 
specific therapeutic groups. In fact studies have been conducted in diverse areas such as 
chronic diseases,(9) reproductive health (26, 27) or ARV drugs.(28) It also has the 
advantage of being specifically validated for low and middle-income settings (22) and 
available online (14), with a comprehensive manual, a pre-programmed data analysis 
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spreadsheet, templates and an exhaustive database including reports from previous 
studies which can serve as basis for future research. Analyses include availability and 
prices of medicines and affordability of common treatments. It also provides tools for 
an additional analysis of government procurement prices and of the components that 
contribute to the final price of medicines.  
 
1.1.5. Access to medicines in low- and middle-income countries: present situation 
By the end of 2007, over 50 surveys had been undertaken across the globe using 
the WHO/HAI methodology described in the previous section. The results of these 
surveys in low- and middle-income countries showed a general pattern of low 
availability of essential medicines, particularly acute in the public sector (where 
medicines are sold at lower prices or dispensed at no cost) forcing the population to 
purchase medicines from the private sector, where they are typically more available, but 
at a higher cost, often considered unaffordable to most of the population.(9,13,14) 
Results also pointed towards a general inefficiency in government procurement 
processes and identified numerous mark-ups, taxes and duties applied along the 
medicines supply chain, which amplify financial obstacles to access. 
In 2008, a second edition of the WHO/HAI project manual was released, with 
updates to the methodology, based on the lessons learned from the field. Several other 
surveys have been carried out in low- and middle-income countries since 2008 and data 
was made available on the WHO/HAI Project on Medicine Prices and Availability 
database.(23) 
The World Medicines Situation 2011 report, a pooled analysis of 53 studies on 
medicines prices, availability and affordability, completed between 2001 and 2008 (8) 
revealed a low availability in the public sector of both generic medicines (lowest price 
generics – LPGs) with less than 60% across all world regions, and originator brands 
(OBs), with governments generally favouring the procurement of generic medicines. In 
the private sector, generic medicines availability was higher than in the public sector 
across all world regions, but also lower than 60%; as for originator brands, availability 
in the private sector was globally lower than 25%, with the exception of the Eastern 
Mediterranean region. Most of the studies covered in this report followed the first 
edition (2003) of the WHO/HAI Project on Medicine Prices and Availability manual. 
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Table 1.1. below shows the most recent data from medicines prices and 
availability surveys conducted with WHO/HAI methodology between 2008 and 2011	  in 
low- and lower-middle-income countries, included in WHO/HAI database.  
 
Table 1.1. Mean availability of essential medicines1 in low- and lower-middle-income 
countries,2 recently surveyed. 
Country 
Public sector 
mean availability (%) 
Private sector 
mean availability (%) 
OB LPG OB LPG 
India (NCT state) 0.0% 32.8% 29.3% 68.8% 
Indonesia 4.6% 55.1% 27.1% 49.4% 
Burkina Faso 0.2% 72.5% 44.1% 63.5% 
São Tomé and Príncipe 2.5% 55.1% 10.8% 24.3% 
Haiti 1.9% 23.3% 6.4% 44.6% 
Guatemala  – 3 46.0%  – 3 35.0% 
Bolivia 0.2% 29.2% 4.7% 74.0% 
Nicaragua 2.4% 47.8% 18.0% 72.9% 
1Results reflect overall availability of a basket of medicines, which may be different across countries 
surveyed.  
2World Bank’s classification 
3Data for OB not available. 
 
Although the common pattern of lower availability in the public sector when 
compared to the private was confirmed in many of these surveys, countries such as 
Indonesia, São Tomé and Príncipe, Burkina Faso and Guatemala seem to show an 
opposite trend. 
In low- and middle-income countries, medicines represent out-of-pocket 
expenses for the majority of the population, since few of these countries have social 
insurance or health services subsidized by public funds.(29) Even in countries where 
medicines in the public sector are provided free of charge, their low availability often 
forces patients to purchase them in the private sector, incurring in significant 
expenses.(8,9) The same medicines show important price variations between countries 
and are sometimes even more expensive in developing countries when compared to 
industrialized nations.(30) Moreover, many studies have shown that affordability is 
unrelated to purchasing power.(14) 
Medicine prices can be standardized to median price ratios (i.e. ratio local 
price/international reference price – refer to Chapter 2. Methods), to allow comparisons 
between countries. While direct price comparisons of individual items should be 
avoided, since they are relatively complex and require adjustments to several factors 
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(like standardizing to the same reference price year for studies carried out in different 
years, adjust for inflation/deflation and for the local currency’s buying power),(14) with 
a sample or basket of medicines it is possible to have a rough idea of how more 
expensive medicines are, in general, in one country or region, when compared to others. 
Table 1.2. below shows a summary of median price ratios for a basket of essential 
medicines (only generic versions) across countries surveyed in the period 2008-2011.  
 
Table 1.2. Median price ratios in the private sector of generic medicines1 in low- and 
lower-middle-income countries,2 recently surveyed. 
Country 
Median Price Ratio – Private sector patient prices 
(all LPG medicines surveyed) 
N Median MPR Min MPR Max MPR 
India (NCT state) 43 2.83 0.56 9.73 
Indonesia 37 2.00 0.46 10.42 
Burkina Faso 43 2.92 1.21 12.56 
São Tomé and Príncipe 39 13.76 0.09 107.51 
Haiti 34 7.25 2.26 49.57 
Bolivia 48 4.54 0.38 52.39 
Nicaragua 41 5.73 0.69 21.30 
1Results reflect overall availability of a basket of medicines, which may be different across countries 
surveyed.  
2World Bank’s classification 
	  
The high prices of medicines invariably contribute to the unaffordability of 
pharmacological treatments. Results from more than 50 studies undertaken by the end 
of 2007 identified one-month treatments costing more than the equivalent to several 
day’s wages of a common government worker in some countries.(14) In a recent survey 
carried out in São Tomé and Príncipe, for instance, treatment of common adult 
respiratory infection with a 7-day course of treatment with ciprofloxacin (500 mg, 
tablets) or ulcer with omeprazol (20 mg, capsules), both generic medicines, was found 
to cost close to 40 day’s wages.(31)	  
The situation is obviously aggravated if patients suffer from chronic conditions 
and purchase the same medicines on a regular monthly basis for instance, or in the case 
of concomitant conditions requiring more than one medicine. In Ghana and El Salvador, 
for instance, concomitant monthly treatment of diabetes and hypertension were found to 
cost 10 or more times the daily wage of a common unskilled government worker.(8) 
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1.2. TIMOR-LESTE: COUNTRY OVERVIEW 
Timor-Leste is located in the southernmost island of the Indonesian archipelago 
in Southeast Asia, occupying a territory of approximately 15.000 km2 which comprises 
the eastern half of Timor island, Atauro and Jaco islands (to the north and to the east, 
respectively), and the Oecussi enclave on the north-western side of the island, within 
Indonesian borders (Figure 1).  
Historically, the territory was under Portuguese colonial rule since the 16th 
century, and started a decolonization process in 1975, which culminated in a declaration 
of independence that launched the country into a civil war. Using the pretext of 
protecting its citizens in the Timorese territory, Indonesia invaded the eastern part of the 
island and annexed the territory as its 27th province nine days after the declaration of 
independence. For 25 years, Timorese kept a resistance movement fighting against the 
integration into Indonesia, which cost the lives of about one third of the population.  
In 1998, under fierce international pressure, Indonesia accepted a referendum in 
East Timor territory in which people would be given the choice of autonomy (and 
integration into Indonesia) or independence. The referendum was held in 1999 and the 
population massively voted for independence. A wave of murders and mass destruction 
promoted by the pro-Indonesian militias and supported by members of the Indonesian 
army followed the announcement of the referendum results. The destruction of 
infrastructures (including many healthcare facilities and roads) was a serious setback to 
the development of the new fragile nation.  The UN finally intervened, militaries were 
deployed to the country and a peacekeeping mission was established with the objective 
of disarming the militias and supporting the transition process and the country’s 
reconstruction. Following this UN transitional administration (UNTAET), Timor-Leste2 
finally became an independent nation on the 20th of May 2002,(32) the date of the 
country’s first constitution.  
The first four years of independence witnessed several gains in capacity, like the 
establishment of tax and customs services and the delivery of health services. However, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2Since 2002, the country’s official name is Timor-Leste (short for Democratic Republic of Timor-Leste), 
but throughout its history, this same territory has been known under different names: ‘Portuguese Timor’, 
during the period of Portuguese colonization (1512-1975), and ‘East Timor’, during Indonesia’s time 
until the country became an independent sovereign state (1975-2002). Some reports and international 
media still refer to Timor-Leste using this last designation. 
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the government faced serious challenges during the post-independence phase, in terms 
of financial management and budget execution and a discontentment wave started to 
emerge among certain sectors of the society.(33) This military and civil uprising, 
coincident with the peacekeepers departure and the scaling down of UN activities, led to 
a crisis in 2006, which forced the Prime Minister to resign. Along with some casualties, 
this crisis led also to the displacement of approximately 15% of the population to 
temporary internally displaced people camps throughout the country, especially in Dili 
area. Upon Timor-Leste’s official request for military assistance, international troops 
returned to the country to restore peace and the UN Security Council established an 
Integrated Mission in Timor-Leste (UNMIT), allowing for new presidential and 
parliamentary elections to take place in 2007, under international observation. This 
international presence was also crucial on the aftermath of the (unsuccessful) rebel 
attacks against the President (and Prime Minister) in February 2008. Fortunately, this 
episode had no serious consequences, and, since then, the country has enjoyed one of its 
longest periods of stability and economic growth. 
According to the latest population census, Timor-Leste has an estimated 
population of 1.066.409 inhabitants and is administratively divided in 13 districts: Aileu, 
Ainaro, Baucau, Bobonaro, Cova-Lima, Dili, Ermera, Lautem, Liquica, Manatuto, 
Manufahi, Oecussi and Viqueque (Figure 1). Each of the districts comprises 4 to 7 sub-
districts, further divided into sucos (villages). The main urban centres are Dili and 
Baucau (122 km east of Dili) but less than one third of the population is urban.3 
Timor-Leste’s official languages are Tetum and Portuguese; Indonesian bahasa 
is no longer an official language but, along with English, it has the status of a ‘working 
language’ under the Constitution. The country uses the north-american dollar (USD) as 
its circulating currency. 
Despite all the country’s achievements in terms of human development since 
independence (Timor-Leste currently occupies the 147th world position of the Human 
Development Index),(34) some indicators, namely in the health sector, still reveal the 
important challenges the country has yet to overcome.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3Census 2010. Available from: http://dne.mof.gov.tl/ (accessed on 22 Jul 2012). 
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According to World Bank’s latest data (2007), half of the population (49.9%) 
lives below the national poverty line and 37.4% below the poverty threshold of 1.25 
USD/day4.(35) 
 
Figure 1. Timor-Leste: administrative division (13 districts). 
 
Source: Ministry of State Administration and Territorial Management of Timor-Leste. Available from: 
http://www.estatal.gov.tl/English/Municipal/Municipal_main.html (accessed on 22 Jul 2012) 
 
 
1.2.1. Timor-Leste’s National health system (NHS) 
The Timorese health sector was critically affected by the devastating events that 
followed the vote for independence in 1999. It is estimated that more than one third of 
the existing health facilities were totally destroyed and most of the remaining 
infrastructures substantially damaged, a considerable part of the equipment had been 
stolen or was completely destroyed and more than 80% of medically qualified staff had 
returned to Indonesia.(36) The international community had to strongly assist the 
Timorese with the rehabilitation of the health system since very few nationals were 
experienced in health administration. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4Poverty headcount ratio at $1.25 a day (PPP) (% of population). 
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The Constitution of the Democratic Republic of Timor-Leste was approved in 
May 2002 and the Ministry of Health (MoH) was officially established later in 
September of the same year. The right to health and health assistance is referred in 
Timor-Leste’s Constitution,5 as one of the basic rights of the population. In 2004, the 
Law on the Health System (Law no. 10/2004) was published, laying basis for the 
creation of a National Health Service of Timor-Leste (NHS) characterized for ‘being 
universal with regard to the target population’, ‘assuring users equal access’ and ‘being 
inclined to be free of charge’. The NHS covers all Timorese citizens, as well as foreign 
nationals with residence in Timor-Leste.(37)  
In addition to the NHS, the Timorese health system includes ‘all other entities, 
public or private, whether lucrative or non-lucrative, which are directly or indirectly 
engaged in health prevention and promotion and disease treatment activities’, such as 
private pharmacies and private clinics.(37) 
On the organizational chart of the MoH, under the National Directorate for 
Community Health, there is a Department of Pharmaceutical Services6 (also known as 
Department of Pharmacy, DOP) whose responsibilities include the development and 
supervision of programs and protocols promoting the rational use of medicines, assuring 
an efficient management of pharmaceutical products for the NHS and providing 
technical support to other authorities of the MoH for inspection and monitoring 
activities. 
In the public health system, there are five levels of care. Level 1 (Health Posts 
[HP] and mobile clinics) include curative consultation, antenatal and postnatal care, 
immunization, growth monitoring and health promotion activities; level 2 Community 
Health Centres (CHC) provide promotion, prevention and curative services, including 
outpatient consultations and a simple laboratory; level 3 CHCs include all services 
provided at lower levels as well as basic emergency obstetric care and 5 to 10 
observation beds; level 4 health centres include an inpatient department with 10 to 20 
beds and include all services provided at lower levels and referral to higher levels if 
needed.(38) Finally, there is a network of 6 referral hospitals: Guido Valadares National 
Hospital in Dili (with 260 beds), Baucau Hospital (with 114 beds), Maliana, Suai, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5Constituição da República Democrática de Timor-Leste. Available from:  
http://www.jornal.gov.tl/public/docs/ConstituicaoRDTL_Portugues.pdf (accessed on 22 Jul 2012) 
6Departamento de Serviços Farmacêuticos  
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Maubisse and Oecussi Hospitals (with 24 beds each).(38, 39) Under agreement with 
certain international organizations, patients can be referred from Dili National Hospital 
to other hospitals overseas, if needed.(40) 
The stratification of healthcare facilities in the Timorese NHS is presented in 
Table 1.3. 
 
Table 1.3. Public healthcare facilities in Timor-Leste by level of care.(41, 42) 
Level Type of facility Location Area of influence 
No. of 
facilities 
1 Health Posts/Mobile Clinics (SISCa) Sucos/remote communities  210/473 
2 Community Health Centres L2 Sub-district urban centres 
1000-5000 
inhabitants 59 
3/4 Community Health Centres L3* / L4# District capitals 
5000-15000 
inhabitants 7 
5 Referral Hospitals/ National Hospital (Dili) 
District 
capitals 
Entire district 
population 6 
SISCa: Serviços Integrados de Saúde Comunitária (Community Integrated Health Services) 
*Level 3 facilities are available in districts with no referral hospital bordering Dili: Aileu and Liquiçá. 
#Level 4 facilities are available in districts with no referral hospital: Lautem, Viqueque, Manufahi, 
Ermera and Manatuto districts. 
 
In the public health system, drugs are provided free of charge to all patients at all 
levels of care. The 2010 edition of the Essential Medicines List (EML) defines the 
level(s) of care for which each medicine should be available.(43) 
Sub-district health centres and higher levels include a Division of Pharmacy 
among their minimum services to ensure a ‘continued availability of pharmaceuticals 
and consumables for the effective provision of the services assigned to the health 
centre.’(40) Currently, a pharmacy assistant or pharmacy technician is usually in charge 
of this department. 
Procurement, storage and distribution of medicines and medical products for the 
public health system is carried out by a semi-autonomous central supply agency, 
Autonomous Drugs and Medical Equipment Service (SAMES)7, established by the 
Government Decree No. 2/2004.(44) SAMES receives its budget directly from the 
Ministry of Finance and is not allowed to supply the private sector. The agency is also 
responsible for storage and distribution of drugs procured for vertical programs (e.g. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7Serviço Autónomo de Medicamentos e Equipamentos de Saúde. 
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UNICEF, UNFPA and Global Fund). SAMES distributes medicines to hospitals on a 
monthly basis and to District Health Offices (DHO) in the districts on a quarterly 
basis;(45)  staff from health posts and health centres must then collect their deliveries 
from the DHO (located in the district capital).  
 
1.2.2. Private for-profit and other sectors providing healthcare in Timor-Leste 
It is estimated that private healthcare facilities account for about one fourth of 
the basic health services provided in Timor-Leste.(46) 
According to the information provided by the DOP, in July 2011 there were 28 
licensed private pharmacies in Timor-Leste, the vast majority of which situated in Dili 
[22] and a few others in four urban centres in the districts – Baucau [3], Liquiçá [1], 
Maliana [1] and Viqueque [1].  
Private not-for-profit clinics also provide health services throughout the country. 
For example, one NGO based in Dili runs eight fixed clinics (with services similar to 
the ones provided in public CHCs) and 24 mobile clinics in Dili and five other districts. 
Additionally, there are 32 mission clinics and other church related facilities working 
mostly with volunteers. Many of these clinics provide medicines at no cost to their 
patients.(46)  
In 2011 there were 11 registered private importers of medicines and medical 
products in Timor-Leste, but no wholesalers or distributers of drugs. As there is no local 
manufacturing, all drugs available in the private sector are all imported, in most cases 
from Indonesia,(47,48) and are manufactured in India or Indonesia. Private importers 
have to previously register all imported medicines, but there are restrictions for certain 
medicines or therapeutic classes (e.g. psychotropic drugs and narcotics can only be 
imported by SAMES).  
 
1.2.3. Human resources in the health sector 
As in other nations in similar stages of development, human resources for health 
in Timor-Leste are insufficient. In the period of 2004 to 2010, the number of trained 
physicians per 1000 inhabitants has increased from 0.10 to 0.22.(41,49) However, it 
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remains below world and regional average numbers, much like the number of nurses 
and midwifes.(50) 
The latest available data on pharmaceutical professionals accounts for a density 
of 0.02 pharmacists per 1000 inhabitants.(49) From 2000 through 2005 there were no 
Timorese pharmacists with university training practicing in Timor-Leste.(45) In 2004 
the Pharmacy Association8 had 43 members, all pharmacy assistants who had in most 
cases received training in Indonesia.(45) During the same period, technical assistance in 
pharmaceutical issues was provided by expatriate consultants, employed or recruited 
through international agencies and organizations. In 2008, the government introduced a 
one-year course in pharmacy (Diploma 1, Pharmacy technician) at the National Institute 
of Health.9  
Currently, there are 11 pharmacists (bachelor degree), 50 pharmacy technicians 
(diploma I) and 106 pharmacy assistants (certificate level) in the country.(51) Many of 
these pharmacy technicians and assistants are responsible for drug management and 
monitoring in the pharmacy division of Community Health Centers and Hospitals; in 
HPs, nurses usually carry out such activities. 
However, because most of this personnel lack adequate management skills, and 
no standard procedures are used, records of drug stocks are not consistent and depend 
on the individual organization of the pharmacy technician in charge. This obviously 
affects the supply by SAMES, which is based on the information provided by each 
individual facility, often miscalculated.(51) 
 
1.2.4. Pharmaceutical sector regulation 
In Timor-Leste as in many other low- and middle-income countries, the 
pharmaceutical sector is poorly regulated and implementation of the existing regulation 
is difficult due to important constraints in human and financial resources (which limit 
inspection activities for example). A summary of the main laws, regulations and other 
official documents affecting the pharmaceutical sector is presented in Table 1.4. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8Associação dos Farmacêuticos de Timor-Leste. 
9Instituto Nacional de Saúde, former Instituto de Ciências da Saúde de Timor-Leste. 
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Table 1.4. Summary of current legislation relevant to the pharmaceutical sector in 
Timor-Leste.10 
Document Description 
Decree Law No. 1/2008 Organic Statute 
of the Ministry of Health (Revoked the 
Government Decree No. 05/2003) 
Establishes the structure of the public health sector, 
including services under direct state administration (such 
as the Department of Pharmacy) and indirect state 
administration (such as SAMES). 
Government Decree No.2/2004 
Autonomous Drug and Medical 
Equipment Service 
Creates SAMES as the public agency for import, storage 
and distribution of medicines, medical equipment and 
other medical consumption goods 
Decree-Law No.12/2004 
Pharmaceutical Activities 
Regulates the exercise of pharmaceutical activities and 
creates CRAF, the Regulating Commission of 
Pharmaceutical Activities 
Ministerial Statute No.5/2004 
Technical Rules for the Functioning and 
Good Practice of Pharmacies 
Guidance on good practices for pharmacy premises, 
medicines storage, equipment, pharmacy staff, drug 
prescription and dispensing. 
Ministerial Statute No.6/2004 
Conditions of Hygiene and Technical 
Adequacy of Installations and Means of 
Transport of Pharmaceutical Activities 
Establishes the basic infrastructures and conditions for 
pharmacies, warehouses and vehicles used in medicines 
transport. 
Ministerial Statute No.7/2004 
Applicable Rules for Donations of 
Medicines, Medical Consumption 
Goods, Medical Equipment and others, 
to Health Institutions 
Defines the minimum requisites for donation of 
medicines and other medical products, for the public and 
private sectors. 
Ministerial Statute No.8/2004 
Labeling and Informative Brochures 
Specifies the mandatory contents of drug labels and 
information leaflets, including permitted languages. 
Decree-Law No.14/2004 (amended by 
Decree-Law No. 40/2011) 
Practice of Health Professions 
Establishes the fundamental requisites for the practice of 
health professions, including pharmacy staff 
Law No.10/2004 
Law on the Health System 
Establishes a legal basis for the national health system, 
including the role of pharmaceutical and complementary 
activities. 
Ministerial Statute No.1/2008 
Organic Statute of Central Health 
Services 
Defines the structure of the Ministry of Health at central 
level, including the duties and responsibilities of each 
directorate and department.  
Ministerial Statute No.3/2008 
Organic Statute of District Health 
Services 
Defines the structure and stratification of primary health 
care provided in district facilities, including the duties 
and responsibilities of the Division of Pharmacy. 
Law No.8/2008 
Taxation Law 
Defines payable taxes for imported goods (including 
medicines) and business activities. 
Decree-Law No.2/2009 
Special Legal System on Supply to the 
Autonomous Department for Drugs and 
Health Equipment 
Defines standard procedures for the procurement of 
medicines, medical equipment and other medical 
consumption goods to be followed by SAMES. 
Ministerial Statute 
No.7/2011/VGC/MS 
Regulating Commission of 
Pharmaceutical Activities (CRAF) 
Reactivates CRAF, expands the commission to sectors 
not previously represented and reinforces the 
commission’s regulatory activities. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
10All legislation available from: http://www.jornal.gov.tl/  
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1.2.5. Timor-Leste’s pharmaceutical system 
The Decree-Law No. 12/2004 regulates the ‘exercise of pharmaceutical 
activities relating to import, storage, export and sale, in bulk or retail, of medicines for 
human use’.(52)	   This legislation established a Regulating Commission of 
Pharmaceutical Activities (CRAF), 11  a basic regulatory authority, composed by 
representatives from several government departments, which is responsible for granting 
licenses to pharmacies and companies with activities related to import, storage, 
distribution, sale and export of medicines. However CRAF is not an executive body and 
most regulatory activities, like the inspection of pharmacies, are actually carried out by 
the Department of Pharmacy. The DOP has other functions (such as supervising drug 
management in public health facilities, developing guidelines and recommendations), 
and relies on a reduced budget and staff number, so regulatory activities are very 
limited.(45,47,51)  
The regulation of pharmaceutical activities provides for the establishment of 
good pharmacy practices, hygiene conditions of facilities and vehicles used for the 
transport of drugs, drug donations, drug labeling and fees applicable to pharmaceutical 
activities. All these aspects have been covered in subsequent ministerial orders; 
however, most of these requisites lack full implementation and/or inspection.(47,51) 
For example, according to the legislation, pharmacies must have a technical manager 
(pharmacist, pharmacy technician or pharmacy assistant), who should be present in the 
pharmacy for the entire working period, to supervise all activities related to drug 
dispensing. However this requisite is not followed by most private pharmacies where 
dispensing is generally done by unqualified staff.(51) Free dispensing of prescription-
only drugs (e.g. antibiotics), is frequent as well as illegal selling of controlled drugs (e.g. 
psychotherapeutic drugs and narcotics); in 2011, three private outlets had their licenses 
confiscated following an DOP inspection.(51) 
 
1.2.6. Procurement, storage and distribution of medicines  
A centralized procurement and supply agency, SAMES, aimed at ‘improving 
and rendering more efficient the supply of drugs, medical equipment and other medical 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11Comissão Reguladora das Actividades Farmacêuticas. 
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consumption goods to institutions belonging to the health system, in particular to the 
National Health Service’ was created in 2004.(44) SAMES falls out of the scope of 
public procurement regulation and its activities follow legal procedures specifically 
created for the procurement of drugs and other medical goods (Decree-Law No. 
2/2009).(53) SAMES is able to import all drugs pertaining to the EML without any 
additional license. Referral hospitals can require non-EML medicines, for which a 
previous approval (by CRAF) is required.  
Currently, SAMES is not allowed to sell any products to the private sector and 
its budget comes directly from the Ministry of Finance. In 2011, the budget was about 
3.8 million USD, but has been increased to 5 million USD in 2012. Additionally to the 
yearly budget, SAMES receives medicines for vertical programs from international 
agencies.(51) 
Selection is made from the list of medicines included in the national EML, from 
pre-qualified suppliers, based on quality performance criteria; according to the 
regulations of the procurement process, this pre-qualification procedure should be done 
on a yearly basis. Depending on the amount involved or responding to exceptional 
circumstances, procurement can be done by (i) open tendering (open to national and 
international suppliers); (ii) partial invitation (pre-qualified suppliers); (iii) request for 
quotations (to a minimum of three known suppliers); or (iv) direct agreement (when 
special conditions apply or in emergency situations).(53) Bid evaluation, based on 
delivery deadline, goods quality and price criteria, is done by an appointed committee. 
Except for pre-qualification of suppliers based on technical specifications provided by 
suppliers, quality of imported drugs is hardly ensured.(45,47) Although SAMES 
established a small laboratory to test medicines quality in 2011, it is still poorly 
equipped (only dissolution tests for tablets can be performed) and testing is therefore 
very limited.(51)  
In addition to SAMES, 11 private companies are also authorized to import and 
distribute medicines in Timor-Leste; most of the medicines imported in the private 
sector come from Indonesia. Private importers need to register all medicines prior to 
importation, but there is no evaluation based on the medicines technical file and no 
post-commercialization pharmacovigilance program. There is also no quality testing of 
drugs available in the private sector, no complete list of the medicines currently 
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registered in the country and no accurate information on how many drugs are actually 
on the market.(51) 
Under the recent Decree-Law on Fair prices (DL No. 29/2011)(54) medicines 
should be subject to a monitored price regime (i.e. companies have to communicate 
their prices and margins to the competent authorities upon notification), but there is 
currently no regulation for setting prices or fixed margins for medicines at any stage of 
the supply chain. 
 
1.2.7. Medicines taxes, duties and fees  
A registration fee (due to the DOP) is required for all drugs imported to Timor-
Leste, except in the case of SAMES. Additionally, all imported medicines (including 
medicines imported by SAMES) are subject to an import duty (2.5%) and sales tax 
(2.5%); medicines are exempt from the excisable tax applied to other imported goods, 
under the general Taxation Law (Law No. 8/2008).(55) 
Apart from the above-mentioned taxes, no other taxes or fees are imposed on 
medicines at any stage of the supply chain. There are no port or airport inspection fees, 
no intermediaries in transport and/or storage of medicines (and therefore, no added 
mark-ups at this stage) and no additional taxes due to any other entity. Medicines 
procured for the public sector are stored in SAMES warehouse in Dili and distributed to 
the country’s health facilities by the Ministry of Health. Private importers have their 
own warehouse facilities and local buyers generally use private vehicles to transport 
medicines. 
 
1.2.8. Other relevant official documents – Essential medicines list (EML), Standard 
Treatment Guidelines (STGs) and National Drug Policy (NDP) 
The first edition of an Essential Medicines List was published in 2003 and 
revised in 2004. In 2010, the DOP released a new edition including approximately 380 
drugs categorized by level of facility where they should be available. Although it 
represents a big effort towards prescription standardization and rational use of 
medicines, this new EML edition (43) has been criticized for its format (not very 
practical for prescribers) and content (inconsistencies in medicines selection and a large 
 22 
number of medicines included).(51) The DOP plans to release an EML update on a 
yearly basis. 
To promote the rational use of drugs, a series of standard treatment guidelines 
(STG) were also updated in 2010,(56) covering primary and hospital care of the most 
common health conditions. A study on the adherence to previous versions of STGs for 
anti-retrovirals and malaria and diarrhoea treatments (39) reported a good knowledge of 
STGs, a favourable adherence profile and a generally positive impact of these STGs on 
medicines prescription patterns in CHCs. However, other more recent reports indicate 
that many practitioners do not follow guidelines because they find them not suitable, not 
matching medicines included in the EML, not translated into some of the working 
languages (STG for referral hospitals are written in English and for primary care in 
Portuguese, which limits the access of health personnel speaking Tetum and 
Indonesian), scarcely distributed (sometimes one copy per facility), and some health 
professionals were not even aware of their existence.(45,51) 
An official national drug policy, establishing a full Drug Regulatory Authority 
was published in 2010, but most aspects covered have not been implemented. A new 
pharmacy law has also been under discussion, but to the present date no such document 
has been approved by the National Parliament.(45,51) 
 
1.2.9. State of the art on availability, prices and affordability of medicines in 
Timor-Leste 
Some availability and price surveys have been conducted in other countries 
within the Southeast Asia region, namely in Indonesia, India, Nepal, Sri Lanka and 
Thailand. In Timor-Leste, there is very little information on the availability of 
medicines within the public sector, due to an unreliable information system (47) and as 
for the private sector, there are no known reports specifically focused on the availability 
of medicines. 
It is estimated that medicines represent one third of the overall costs of obtaining 
outpatient care in Timor-Leste (the higher costs are travel expenses to reach healthcare 
facilities).12 Although no study has been conducted to describe the availability, prices 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
12Rannan-Eliya, RP. Out-of-pocket spending and health care inequalities in Timor Leste [unpublished]; 
2011. 	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and affordability of medicines in Timor-Leste as yet, these sort of problems have been 
identified in similar countries in Southeast Asia. A first description of the country’s 
situation could therefore be of great utility and lay basis to subsequent studies or 
interventions. 
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1.3. AIM OF THE STUDY AND OBJECTIVES 
Accurate information is essential for identifying the sources of poor and/or 
unequal access to pharmacological treatments and for planning any potential actions to 
address these issues. The aim of the present study was to investigate the pharmaceutical 
sector in Timor-Leste, exploring the dimensions of availability, prices and affordability 
of common treatments, and to produce evidence that could be disseminated to 
government bodies and other relevant organizations engaged in the pharmaceutical 
sector. The study aimed at providing an evidence base to identify the challenges faced 
by the government in respect to pharmaceutical regulation, with the explicit focus on 
improving the access of the Timorese population to essential medicines, with adequate 
quality and affordable prices.  
 
1.3.1. Aim of the study 
To explore availability and prices of medicines in Timor-Leste, as well as 
affordability of treatments, with the objective to produce evidence that can be used by 
government bodies and institutions as a basis to regulate the pharmaceutical sector. 
 
1.3.2. Objectives 
• To determine the availability of essential medicines in Timor-Leste, in public and 
private for-profit sectors (and the variability across the two sectors); 
• To determine the prices paid by patients/families for medicines (originator brand and 
its generic equivalent) in the private for-profit sector (retail pharmacies); 
• To calculate the cost of a course of treatment, based on medicines prices (originator 
brands and generics) and determine if it is affordable for the population; 
• To compare the results from Timor-Leste with other countries in the same world 
region and other similar countries where availability and price surveys were carried 
out using the same methodology; 
• To produce information that can be disseminated to government bodies and other 
stakeholders in the pharmaceutical sector, providing a basis for a deeper analysis on 
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the access to essential medicines in Timor-Leste and the development of measures to 
strengthen the sector’s regulation; 
• To contribute for the international debate on the availability and prices of essential 
medicines in low-income countries. 	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2. METHODS 
The present study was based on a standardized methodology developed by the 
World Health Organization and the non-governmental organization Health Action 
International (HAI) to measure medicines availability, prices and affordability.(14) The 
objective of this methodology is to obtain standardized and comparable data, which can 
be used as guidance for policy interventions aimed at improving access to medicines in 
low- and middle-income countries. 
The WHO/HAI methodology is detailed in a manual (currently on its second 
reviewed edition) and includes a spreadsheet for data analysis, both of which are 
available online. Accessible on the website is also a database of previous surveys 
conducted with the same methodology as well as related studies, for comparison 
purposes.(23) Technical support is provided to investigators who wish to follow this 
methodology to conduct a survey.  
Survey research is a quantitative approach, where instruments are used to 
observe and measure variables related to the information required according to the 
objectives of the investigation. The resultant quantified data can then be analysed 
through statistical procedures, allowing generalization and replication of the 
findings.(57) This kind of approach was considered adequate and in line with the 
objectives of the present study, since it provides tangible data on the availability and 
prices of medicines that can then be used: (i) to describe the current situation in Timor-
Leste and (ii) to consistently compare the country’s situation with other similar contexts 
and gain a better understanding of the factors that may be affecting the access to 
medicines.  
 
2.1. SURVEY SAMPLE 
WHO/HAI methodology relies on data collected from a sample of outlets where 
medicines are sold and/or distributed to the population: this can comprise the public and 
private sectors as well as other sectors relevant in the country (mission hospitals, NGOs, 
etc.). The WHO/HAI manual recommends a sample of 5 facilities (hospital and 4 
others) within each sector, selected on a basis of proximity to the main hospital, in 6 
different geographic areas.  
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Adaptations to the original methodology were necessary to suit the specific 
context of Timor-Leste and face the limitations encountered during the fieldwork. The 
sample surveyed in our study is described below, per sector. 
 
2.1.1. Public sector facilities 
For the purpose of this study, each of the 13 districts in Timor-Leste was 
considered as a separate geographic area. Our public sector sample was composed of a 
total of 22 public health facilities: 5 referral hospitals (out of 6 in the whole country) 
and 17 sub-district community health centres (out of 66 in the whole country), 
distributed across 5 geographic areas. Despite the fact that this sample is not in full 
accordance with the WHO/HAI recommendations (see Chapter 4. Limitations of the 
present study) more than half (52.1%) of the country’s population live in these 5 
geographic areas and 44.1% is covered by the public healthcare facilities included in 
our sample. Additionally, rural and urban settings are represented: from the 17 health 
centres considered, 9 are located in rural areas and 8 in urban centres. All hospitals are 
located in urban centres. 
 
Table 2.1. Number of surveyed healthcare facilities in urban and rural areas. 
Geographic area Urban1 Rural 
Dili 5 –  
Baucau 2 3 
Bobonaro 2 3 
Covalima 2 1 
Oecussi 2 2 
Total 13 9 
1All hospitals are located in urban centres. 
 
2.1.2. Private sector retail pharmacies 
In the private sector, the particular distribution pattern in Timor-Leste led to the 
decision of surveying all existing private retail pharmacies located in the geographic 
areas selected for the public sector. 
However, from the original list of 28 private pharmacies licensed by the 
Ministry of Health, updated in July 2011, four pharmacies in Dili area were 
automatically excluded for the following reasons: (i) two were already closed when the 
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data collection phase started; (ii) two others were found to be exclusively dedicated to 
Chinese medicines, out of the scope of the present study. 
From the remaining group of 24 retail pharmacies, one (also located in Dili) was 
never open to the public during the whole study period (despite several attempts made 
to visit it and contact the owner/manager) – although the pharmacy’s closure was not 
officially confirmed by the Department of Pharmacy, it could not be visited and was 
therefore excluded. Finally, 2 new pharmacies were located in geographic areas not 
included in the initial protocol and were not possible to include later for reasons related 
to distance and schedule. 
Thus, the private for-profit sector in the present study was represented by 21 
retail pharmacies open to the public and located in four different geographic areas. Out 
of these 21, 16 were located in Dili city and 5 in urban centres of three other districts. 
No private retail outlets are currently registered in rural areas throughout the country.  
Tables 1 and 2 (Appendix 1) show the list of health facilities visited for each 
sector; table 2.2. below summarizes the survey sample per facility type and geographic 
area. 
 
Table 2.2. Survey sample per facility type and geographic area. 
Geographic area Public Hospitals Public CHCs Private pharmacies 
Dili 1 (1) 4  (6) 16 (21) 
Baucau 1 (1) 4 (6) 3 (3) 
Bobonaro 1 (1) 4 (6) 1 (1) 
Covalima 1 (1) 2 (7) – 
Liquiçá – – 1 (1) 
Oecussi 1 (1) 3 (4) – 
Total 5 (6) 17 (66) 21 (24)1 
CHCs: community health centres (sub-district) 
Note: numbers in brackets indicate the total number of the same type facilities within the geographic area 
considered.  
1Initial list of 28 registered private pharmacies provided by the Department of Pharmacy of the Ministry 
of Health (updated July 2011), excluding: (i) pharmacies closed to the public during the survey period 
and (ii) pharmacies exclusively dedicated to Chinese medicines. 
 
2.1.3. List of medicines surveyed 
According to WHO/HAI manual, a typical survey can include a list of up to 50 
medicines, of which 14 belong to a standard core list, 16 to a regional list and 20 are 
supplementary medicines selected on basis of their importance at a national level.  
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A first preliminary version of the list was discussed in a meeting held with the 
Ethics Committee from the Cabinet of Health Research13 (see 2.4. Ethical concerns), 
after which a final list of medicines for our survey was selected. The final list included 
(i) 14 medicines from the WHO/HAI core list14; (ii) 6 medicines from WHO’s SEAR 
regional list14; and (iii) 28 supplementary medicines, chosen from either WHO’s list of 
priority medicines for mothers and children (58) (since maternal, newborn and child 
health [MNCH] is one of the priority areas in Timor-Leste) or a tracer list, previously 
adopted by the MoH to monitor medicines availability in public health facilities 
(currently underused). This tracer list (59) is based on the national EML and includes 
some of the most used medicines according to the country’s disease patterns; in line 
with the CHR’s recommendation, the investigator considered pertinent to include some 
of the medicines from the tracer list in the final list of medicines to be surveyed.  
The final list of medicines for this survey is composed by 48 medicines and 
shown in Table 3 (Appendix 2). 
The dosage form and strength of medicines included in the supplementary list 
was adjusted using the most recent edition of the national EML; international reference 
prices (IRP) were extracted from MSH’s International Drug Price Indicator Guide.(15) 
For medicines included in WHO/HAI core and regional lists, this information is 
automatically available in the spreadsheet provided with the manual. 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
13Gabinete de Pesquisa e Desenvolvimento da Saúde 
14WHO/HAI manual recommends a list of 14 medicines to be included in all surveys for comparison 
purposes; to allow comparisons among countries of the same WHO region, specific regional lists were 
also developed. 
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2.2. DATA COLLECTION 
A standardized data collection form generated by the WHO/HAI software 
(shown in Appendix 3) was used to collect the data in both public and private sectors. 
The data collection phase started with two pilot studies in Dili district: one community 
health centre (public sector) and one private pharmacy (private sector) were surveyed 
and the information provided was used to make final adjustments to the data collection 
form (namely in dosage forms and target pack sizes).   
The principal investigator visited all outlets, public and private, in all geographic 
areas, and information was collected with the support of the pharmacist/nurse in charge 
of the dispensary and/or pharmacy warehouse, in the case of hospitals and CHCs. As for 
private pharmacies, information was either provided by the owner, responsible 
pharmacist or, in most cases, by any other non-technical pharmacy staff member. In 
private pharmacies, as well as in hospitals, it was sometimes necessary to set an 
appointment beforehand, but in CHCs it was generally possible to conduct the survey 
immediately at the time of the first visit.  
The data collection phase took place between November 2011 and January 2012, 
over a period of approximately 9 weeks. Data collection forms were in English 
language15, but verbal contacts were usually made in Tetum and/or Portuguese and only 
in a few cases in English. 
 
2.2.1. Availability of medicines (public and private sectors) 
Availability of all medicines included in the selected list was determined on the 
day of data collection, in both public health facilities and private pharmacies. For each 
active substance two products were surveyed: the originator brand (OB) and the lowest 
price generic equivalent (LPG). OBs were previously selected for each medicine while 
LPGs were determined in loco at the time of data collection. In the case of medicines 
for which no originator brand is available, the field is automatically excluded from the 
data collection form and does not count for the availability final results. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
15As medicines were presented in the formulary under international non-proprietary name (INN) or 
generic name, language-related communication problems were not expected to affect data collection at 
this point. 
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To be marked as ‘available’, a medicine had to be physically observed by the 
investigator; in the public sector, for instance, not all medicines were usually available 
within the pharmacy premises and other departments such as the maternal health, family 
planning or vaccination room were also visited. 
 
2.2.2. Medicines prices (private sector) 
In private pharmacies, medicines prices (for both OBs and LPGs) were also 
collected on the day of visit using the same data collection form. If the target pack size 
for one given medicine was not found in the outlet, the closest available pack size was 
selected in loco. Depending on the type of medicine, prices were then converted into 
unit prices (i.e. per tablet, ml, dose, etc). All prices were directly collected in US dollars 
(Timor-Leste’s official currency), so no conversion was necessary. 
 
2.2.3. Medicines procurement prices (public sector) 
Data on public procurement prices was obtained from 3 different contracts for 
the provision of medicines and other health products celebrated during 2011 between 
SAMES or MoH and different suppliers: one was an international contract and the 
remaining two were from a local importer/supplier. The currency used in all contracts 
was the US dollar. 
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2.3. DATA ANALYSIS 
Data analysis was conducted using the workbook (MS Excel pre-programmed 
spreadsheet) provided with the WHO/HAI manual.(14) The investigator entered all data, 
which was then double entered by a second person, not related to the study, and finally 
checked using the checking tool integrated in the software, to correct all discrepancies 
and ensure maximum reliability.  
After data entry is completed, the workbook is automatically designed to 
perform the following analysis: 
(i) Mean availability of medicines, in all sectors included in the analysis (public 
and private for-profit in the case of Timor-Leste); 
(ii) Medicines patient prices, presented as median price ratios (only for the 
private for-profit sector in the case of Timor-Leste) 
(iii) Public sector procurement prices, presented as median price ratios; 
(iv) Number of day’s wages equivalent to a standard course of treatment with 
medicines for which ≥ 4 prices were found (with branded and/or generic medicines). 
 
2.3.1. Availability of medicines 
Defined as the percentage of medicine outlets in which the medicine was found 
on the day of data collection. The mean availability was calculated for both public and 
private sectors and for originator brands as well as lowest-priced generic equivalents for 
the initial basket of 48 medicines. 
In the case of 8 medicines, no originator brand is available; such medicines were 
automatically excluded in the workbook not to influence the overall availability analysis 
for both public and private sectors. Four other medicines were excluded from the 
private sector analysis. All exclusions from the original medicines list and respective 
rationale are presented in Table 2.3. below.  
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Table 2.3. Medicines from originally included in the survey list (n=48) but excluded 
from the final analysis and respective rationale, per sector and medicine type. 
Medicine name Public/ Private OB/LPG Justification for exclusion 
Artemether/Lumefantrine Private Both Only procured for the public sector (via Global Fund) 
Calcium gluconate Both OB No OB 
Diazepam 5mg Private Both Only the SAMES is officially allowed to import psychotropic drugs 
Ferrum sulphate Both OB No OB 
Folic acid/Ferrum sulphate Both OB No OB 
Magnesium sulphate  Both OB No OB 
ORS Both OB/LPG No OB/ LPG in a different pack size  
Paracetamol suspension Private OB OB comes in a different dosage 
Ringer’s lactate Both OB No OB 
Tetanus toxoid vaccine Both OB No OB 
Vitamin A Both OB No OB 
OB: originator brand; LPG: lowest price generic; ORS: oral rehydration salts. 
 
2.3.2. Medicines prices (private sector) 
Since medicines are distributed free of charge in the public sector, the analysis 
of patient prices was only conducted for the private sector. For comparison purposes, all 
prices found in retail pharmacies were calculated per unit dose and median results for 
each substance presented as a median price ratio (MPR); this ratio reveals how much 
higher or lower a price is in comparison to its international reference price (IRP) and is 
calculated dividing the price of a given medicine by its respective IRP. For instance, a 
medicine for which MPR = 1 has a price equivalent to its international reference price, 
whereas a medicine with MPR = 2 costs twice as much and conversely a MPR = 0.5, 
indicates the medicine costs half its IRP.  
International reference unit prices were extracted from the 2010 edition of the 
International Drug Price Indicator Guide published by the organization Management 
Sciences for Health. Again in this case, no currency conversion was necessary since 
IRPs are presented in US dollars. 
Only medicines found in 4 or more outlets were included to estimate the global 
median MPR, as well as the minimum, maximum and MPR percentiles. The same 
analysis was done for originator brands and generic medicines. 
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2.3.3. Medicines procurement prices (public sector) 
Similarly to the analysis of patient prices, procurement prices, extracted from 
government procurement documents, were presented as a median price ratio (MPR). 
The objective is to assess the efficiency of public procurement: if procurement prices 
are similar to IRPs (i.e. the market’s international reference price), the procurement 
process can be considered efficient. International reference prices were extracted from 
the same source described in the previous section. 
 
2.3.4. Affordability of treatments 
Affordability of purchasing treatment in the private sector was also measured 
according to the WHO/HAI’s approach. The median price of one complete course of 
treatment with medicines included in our list was calculated based on the median prices 
obtained in the private pharmacies, considering the number of days usually required to 
treat a common health problem. For medicines belonging to WHO/HAI core list, the 
workbook is already programmed to calculate a standard course of treatment; for 
medicines included in the regional and supplementary lists, the dosage and treatment 
duration was manually entered, based on common affections described in the last 
edition of the Standard Treatment Guidelines for Timor-Leste.(43) The methodology 
defines courses of treatment for acute conditions as the treatment of one single episode; 
for chronic affections, calculations are generally made for one month of treatment. The 
price of a complete course of treatment was then converted into the number of working 
days of the lowest paid unskilled government worker. The salary of the lowest paid 
government worker was obtained from the government’s salary tables for public 
administration workers.(60) 
According to this approach, a course of treatment that costs up to the equivalent 
of one daily wage of the lowest paid government worker is considered affordable, while 
treatments exceeding that threshold are generally considered as unaffordable.  
Affordability analysis was conducted for originator brands and generic 
medicines, whenever data on prices was found in a minimum of 4 outlets. 
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2.4. ETHICAL AND LEGAL CONCERNS 
Prior to data collection, the protocol was first presented to the Ethical 
Committee of the investigator’s institution (Instituto de Higiene e Medicina Tropical) 
and no ethical or legal issues were identified.  
According to the usual procedures in Timor-Leste, all studies related to health 
topics have to seek approval from the Ethics and Technical Committee of the Cabinet of 
Health Research (Ministry of Health). The authorization request was followed by a 
meeting where the investigator presented the study protocol before the members of the 
committee, who granted permission for the study to take place in Timor-Leste. Some of 
the committee’s suggestions raised during the presentation were integrated in the initial 
protocol (see in Chapter 2.1.3. List of medicines surveyed). 
An introduction letter, explaining the study’s main objectives and procedures 
was always presented to the responsible person of the facility/outlet (or substitute) 
during the first visit. The presentation letter was translated into Tetum, Portuguese and 
English, to minimize language obstacles and ensure that the study’s objectives and 
procedures were clear to all involved staff members before data collection. Whenever 
necessary, the approval document issued by the Ethics Committee was also presented. 
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3. RESULTS 
The results section is structured to reflect the different aspects of general access 
to medicines.  A first part is dedicated to medicines availability in the public and private 
health sectors, followed by an analysis on medicines prices and affordability focussing 
exclusively on the private sector, since medicines in the public sector are distributed 
free of charge to the population. The last part covers the public sector procurement 
process, and procurement prices as compared to international reference prices. 
 
3.1. MEDICINES AVAILABILITY 
3.1.1. Public sector   
Overall, 22 public health facilities were surveyed: 5 referral hospitals and 17 
sub-district health centres, located in five different geographic areas (Dili, Baucau, 
Bobonaro, Covalima and Oecussi districts). The list of the public sector facilities where 
the study was conducted is presented in Table 1 (Appendix 1). 
The national results of the availability survey, as well as the results for each 
district, are presented in Table 3.1. below. Two districts (Dili and Baucau) have an 
overall availability above the national average for generic medicines (but lower among 
originator brands), while Bobonaro and Covalima show a mean availability lower than 
average. Oecussi, has an availability within national average for generic medicines and 
higher than average for originator brands. 
 
  
Table 3. 1. Mean availability (%) of a basket of 48 medicines in public health facilities 
(n=22), per medicine type (OB or LPG) and geographic area. 
District OB LPG 
Dili (n=5) 6.0 67.2 
Baucau (n=5) 7.0 63.0 
Bobonaro (n=5) 7.0 52.3 
Covalima (n=3) 8.3 54.6 
Oecussi (n=4) 8.8 59.6 
National (n=22) 7.3 59.6 
OB: originator brand; LPG: lowest price generic 
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Among sectors, a higher availability was found in hospitals, when compared to 
sub-district health centres (9.5% vs. 8.0% for OB and 66,8% vs. 59.0% for LPG 
respectively). Focusing our analysis to hospitals, the mean availability of generic 
medicines ranges from 76.6% in Baucau Hospital to 55.3% in Maliana Hospital 
(Bobonaro). The hospitals with a higher availability were also the ones where a larger 
number of donated medicines were found (Baucau, Oecussi and Dili).   
As for CHCs, Dili is the area where the highest availability was observed 
(66.9% for LPGs) and Covalima shows the lowest availability among CHCs (52.5% for 
LPGs). When analysing results individually, the highest availability of generic 
medicines was found in one CHC located in Dili (75.0%), while the lowest was found 
in CHCs located in Baucau and Bobonaro districts (both with 47.5%); all these three 
locations had a similar mean availability for OBs: 6.1%. 
The mean availability of generic medicines in the public sector, per district and 
level of care, is presented in Table 3.2., with higher and lower percentages highlighted. 
 
 
Table 3. 2. Mean availability (%) of a basket of generic medicines, per district, in 
hospitals and sub-district level community health centres. 
District Hospitals CHC1 CHC2 CHC3 CHC4 Total CHCs 
Dili 66.0 55.0 65.0 72.5 75.0 66.9 
Baucau 76.6 47.5 70.0 62.5 60.0 60.0 
Bobonaro 55.3 62.5 47.5 55.0 57.5 55.6 
Covalima 66.0 57.5 47.5 — — 52.5 
Oecussi 70.2 62.5 50.0 55.0 — 55.8 
CHC: community health centre 
 
 
A summary of the specific mean availability for each of the medicines surveyed 
in the present study, in the public sector is presented in Table 3.3. It is important to 
mention that the percentages shown may not always reflect the real availability of some 
active substances included in our list; for some medicines the study dosage was not 
found, but there was an alternative dosage available (e.g. ciprofloxacin 250 mg instead 
of 500mg; folic acid and ferrum sulphate individually, instead of combined; vitamin A 
200 MIU instead of 100 MIU) (see also Chapter 4. Limitations). 
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Table 3. 3. Mean availability of medicines in the public sector, per type (OB or LPG). 
No. Medicine OB LPG 
1 Acetylsalycilic acid 0.0% 95.5% 
2 Amitriptyline 0.0% 60.0% 
3 Amoxicillin 0.0% 100.0% 
4 Ampicilin injection 0.0% 72.7% 
5 Artemether/lumefantrine 100.0% - 2 
6 Artesunate 0.0% 4.5% 
7 Atenolol 0.0% 81.8% 
8 Beclometasone inhaler 0.0% 22.7% 
9 Benzathine benzylpenicillin injection 0.0% 59.1% 
10 Calcium gluconate injection -1 9.1% 
11 Captopril 0.0% 90.9% 
12 Cefixime 0.0% 0.0% 
13 Ceftriaxone injection 0.0% 100.0% 
14 Chloramphenicol injection 0.0% 45.5% 
15 Chloramphenicol tablets 0.0% 81.8% 
16 Ciprofloxacin 0.0% 45.5% 
17 Clotrimazole topical cream 0.0% 4.5% 
18 Co-trimoxazole suspension 0.0% 100.0% 
19 Co-trimoxazole tablets 0.0% 77.3% 
20 Diazepam 0.0% 68.2% 
21 Diclofenac 0.0% 80.0% 
22 Doxycycline 0.0% 95.5% 
23 Enalapril 0.0% 20.0% 
24 Ethinyloestradiol/levonorgestrel (COC) 59.1% 0.0% 
25 Ferrum sulphate -1 90.9% 
26 Folic acid + ferrum sulphate -1 72.7% 
27 Gentamicin injection 0.0% 77.3% 
28 Glibenclamide 0.0% 50.0% 
29 Hydralazine 22.7% 4.5% 
30 Hydrochlorothiazide 0.0% 86.4% 
31 Ibuprofen 0.0% 100.0% 
32 Magnesium sulphate injection -1 22.7% 
33 Medroxyprogesterone acetate injection 86.4% 0.0% 
34 Metformin 0.0% 60.0% 
35 Metronidazole injection 0.0% 40.9% 
36 Metronidazole tablets 0.0% 95.5% 
37 Misoprostol 0.0% 20.0% 
38 Omeprazole 0.0% 45.5% 
39 Oral rehydration salts (ORS) -1 95.5% 
40 Oxytocin injection 0.0% 72.7% 
41 Paracetamol suspension 0.0% 86.4% 
42 Paracetamol tablets 0.0% 95.5% 
43 Ranitidine 0.0% 95.5% 
44 Ringer's lactate -1 95.5% 
45 Salbutamol inhaler 22.7% 59.1% 
46 Simvastatin 0.0% 0.0% 
47 Tetanus toxoid vaccine -1 86.4% 
48 Vitamin A -1 31.8% 
OB: originator brand; LPG: lowest price generic; COC: combined oral contraceptive 
Notes: 1Medicine with no originator brand; 2Medicine excluded from the analysis. (see Chapter 2. 
Methods). 
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As shown in the table above, the mean availability of medicines in the public 
sector was clearly higher for generic medicines than for originator brands: 59.6% vs. 
7.3% respectively. This is consistent with the national guidelines, which specify 
preference for the procurement of generic medicines for the national health system. 
Out of the 48 medicines surveyed, only 5 were found as originator brands. Three 
of those belong to either malaria or family planning programs, which follow specific 
procurement procedures (via Global Fund and UNFPA) and are always purchased as 
branded medicines from prequalified suppliers. The remaining 2 (hydralazine injection 
and salbutamol inhaler) were found either as originator brands or generics. 
From our original list, 4 generic medicines were available in all public facilities 
visited (amoxicillin, ceftriaxone injection, co-trimoxazole suspension and ibuprofen), 
21 had an availability ≥ 75.0% and 12 had an availability below 25.0%.  As for 
originator brands, only 2 medicines were available in ≥ 75.0% of the public facilities 
surveyed (arthemeter/lumefantrine and medroxyprogesterone injection). 
If we look at groups of medicines per therapeutic category, it is possible to 
identify higher availabilities among certain groups of medicines (like NSAIDs or oral 
antibiotics, with 90.5% and 74.4%, respectively, for LPGs) and lower among others 
(like priority medicines for MNCH 40.1% if we consider only LPGs, higher if we 
consider both OBs and LPGs, 49.8%). Availability for the medicines comprised in the 
WHO/HAI’s global list (n=14) was 69.1%, while medicines included in the SEAR 
regional list (n=6) show a mean availability of 63.0%; in both cases OBs availability 
was below 2%. The lists of medicines included in this group analysis are presented in 
table 4, Appendix 4.  
 
3.1.2. Private sector 
The private sector in Timor-Leste is represented in this study by 21 private retail 
pharmacies located in 4 different geographic areas: 16 in Dili, 3 in Baucau, 1 in 
Bobonaro and 1 in Liquiçá. A list of all private pharmacies surveyed is presented in 
Table 2 (Appendix 1).  
Table 3.4. shows the mean availability of medicines in the private sector. Most 
pharmacies included in this study are located in the central area of Dili. The pharmacies 
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located outside the capital clearly show a much lower availability, less than half if we 
consider originator brands and slightly more than half in the case of generics, when 
compared to the pharmacies in Dili. 
 
 
Table 3. 4. Mean availability (%) of a basket of medicines in private pharmacies (n=21), 
per medicine type. 
Geographical area Originator brand Lowest price generic 
Dili (n=16) 10.3 42.4 
Districts (n=5) 4.9 24.0 
National (n=21) 9.0 38.0 
 
 
Similarly to the situation observed in the public sector, generic medicines are 
more widely available than originator brands. The mean availability of generic 
medicines in the private sector is lower than in the public sector (38.0 vs. 59.6%); for 
originator brands, the mean availability in the private sector is slightly higher than in the 
public sector (9.0 vs. 7.3%). 
Table 3.5. below shows the mean availability in the private sector for all 
medicines included in our analysis. 
Considering only generic medicines, there are important differences among 
therapeutic groups, even more marked than in the public sector. Oral antibiotics, for 
instance, show in general very high availabilities in private pharmacies (e.g. 
amoxicillin: 95.2%; ciprofloxacin: 90.5%; co-trimoxazole tablets 95.2% and an overall 
group availability of 67.3%), and the same happens with NSAIDs for adults and 
children (with a group availability of 82.1%). The lowest availabilities are found among 
injectables (mostly antibiotics) and medicines that require cold chain storage 
(unavailable in most pharmacies). Medicines for MNCH show in general low 
availabilities (except contraceptives), both OBs and LPGs, and the overall availability 
of medicines in this group (OB and LPG) is 22.4%. Availability of LPGs from the 
WHO/HAI’s global list (n=14) was 60.7%, while medicines included in the SEAR 
regional list (n=6) showed a mean availability of 50.0%; OBs availability was 12.8% 
and 12.7%, respectively. The lists of medicines included in this group analysis are 
presented in Table 4, Appendix 4. 
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Table 3. 5. Mean availability of 48 medicines in the private sector, per medicine type. 
No. Medicine OB LPG 
1 Acetylsalycilic acid 0.0% 4.8% 
2 Amitriptyline 0.0% 14.3% 
3 Amoxicillin 0.0% 95.2% 
4 Ampicilin injection 0.0% 52.4% 
5 Artemether/lumefantrine -2 -2 
6 Artesunate 0.0% 4.8% 
7 Atenolol 19.0% 23.8% 
8 Beclometasone inhaler 0.0% 0.0% 
9 Benzathine benzylpenicillin injection 0.0% 0.0% 
10 Calcium gluconate injection -1 9.5% 
11 Captopril 0.0% 85.7% 
12 Cefixime 0.0% 0.0% 
13 Ceftriaxone injection 0.0% 38.1% 
14 Chloramphenicol injection 0.0% 4.8% 
15 Chloramphenicol tablets 0.0% 76.2% 
16 Ciprofloxacin 0.0% 90.5% 
17 Clotrimazole topical cream 61.9% 14.3% 
18 Co-trimoxazole suspension 19.0% 85.7% 
19 Co-trimoxazole tablets 0.0% 95.2% 
20 Diazepam -2 -2 
21 Diclofenac 23.8% 61.9% 
22 Doxycycline 0.0% 85.7% 
23 Enalapril 0.0% 0.0% 
24 Ethinyloestradiol/levonorgestrel (COC) 76.2% 0.0% 
25 Ferrum sulfate -1 47.6% 
26 Folic acid + ferrum sulphate -1 0.0% 
27 Gentamicin injection 0.0% 33.3% 
28 Glibenclamide 4.8% 57.1% 
29 Hydralazine 0.0% 0.0% 
30 Hydrochlorothiazide 0.0% 52.4% 
31 Ibuprofen 0.0% 85.7% 
32 Magnesium sulphate injection -1 0.0% 
33 Medroxyprogesterone acetate injection 0.0% 61.9% 
34 Metformin 14.3% 38.1% 
35 Metronidazole injection 0.0% 14.3% 
36 Metronidazole tablets 9.5% 9.5% 
37 Misoprostol 4.8% 9.5% 
38 Omeprazole 0.0% 85.7% 
39 Oral rehydration salts (ORS) -1 -2 
40 Oxytocin injection 0.0% 14.3% 
41 Paracetamol suspension -2 90.5% 
42 Paracetamol tablets 85.7% 90.5% 
43 Ranitidine 0.0% 76.2% 
44 Ringer's lactate -1 23.8% 
45 Salbutamol inhaler 14.3% 33.3% 
46 Simvastatin 0.0% 28.6% 
47 Tetanus toxoid vaccine -1 4.8% 
48 Vitamin A -1 9.5% 
OB: originator brand; LPG: lowest price generic; COC: combined oral contraceptive 
1Medicine with no originator brand; 2Medicine excluded from the analysis. (see Chapter 2. Methods). 
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3.2. MEDICINES PRICES 
Medicines in the public sector are distributed free of charge to the population, 
regardless of the therapeutic class or population group. There are also no fees related to 
medical services or any prescription charges in the public health facilities. Patient price 
analysis is therefore not applicable to the public sector in Timor-Leste. 
As for procurement prices, no procurement documents from private 
importers/retailers were collected for this investigation. Analysis of procurement prices 
focussed only on medicines procured for the national health system. 
 
3.2.1. Private sector patient prices 
Only medicines with at least 4 prices obtained in different outlets were included 
in the price analysis. Since generics are more commonly available than originator 
brands in the Timorese private sector, from our original sample of 48 medicines, the 
results were calculated with data obtained from 6 OBs and 25 LPGs and are presented 
in Table 3.6. in this section.  
This table shows that medicines selling prices in the private sector in Timor-
Leste are considerably higher than international reference prices, both for OBs and 
LPGs. Differences are even more substantial among originator brands, with median 
MPRs ranging from 6.40 for oral contraceptives to 186.05 in the case of diclofenac. For 
generic medicines, patient prices are lower than originator brands but still very high 
when compared to their IRP, as high as 36.84 times in the case of atenolol for example. 
Extending our analysis to individual medicines, we can observe an important 
variability in prices across outlets, which is more evident among certain medicines. 
Table 3.7. shows examples of medicines for which maximum price (expressed as MPR) 
was at least 5 times higher than minimum MPR found across outlets surveyed.  
Sometimes, despite the price difference, private pharmacies are the only 
alternative to obtain certain treatments. Clotrimazole 1% topical cream, for instance: its 
price (OB) was approximately 37 times more expensive than the corresponding IRP, but 
it was still available in more than 60% of the private retail pharmacies visited, in 
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contrast with the same medicine distributed free of charge in the public sector but where 
its availability is below 5%. 
 
Table 3. 6. Median MPRs, for medicines with ≥ 4 prices available, per type. 
Medicine name (INN) and 
pharmaceutical form 
MPR Originator brand 
(n=6) 
MPR Lowest price 
generic (n=25) 
Amoxicillin 500mg tablet  3.45 
Ampicilin 1g injection  12.06 
Atenolol 50mg tablet 118.42 36.84 
Captopril 25mg tablet  8.33 
Ceftriaxone 1g injection  3.99 
Chloramphenicol 250mg tablet  6.45 
Ciprofloxacin 500mg tablet  4.90 
Clotrimazole 1% topical cream 37.04  
Co-trimoxazole  8+40mg/ml suspension 57.14 3.95 
Co-trimoxazole  480mg tablet  9.43 
Diclofenac 50mg tablet 186.05 34.88 
Doxycycline 100mg tablet  12.82 
Ethinyoestradiol/Levonorgestrel tablet 6.40  
Ferrum sulphate (60mg Fe) tablet  21.74 
Gentamicin 40mg/ml injection  22.42 
Glibenclamide 5mg tablet  29.41 
Hydrochlorthiazide 25mg tablet  27.03 
Ibuprofen 400 mg tablet  10.64 
Medroxyprogesterone 150mg/ml injection  1.42 
Metformin 500mg tablet  11.90 
Omeprazole 20mg capsule  8.33 
Paracetamol 120mg/5ml suspension  4.26 
Paracetamol 500mg tablet 22.22 11.11 
Ranitidine 150mg tablet  7.50 
Ringer’s lactate infusion  3.33 
Salbutamol 100mcg/dose inhaler  4.41 
Simvastatin 20mg tablet  5.11 
MPR: Median price ratio (ratio median observed price/International Reference Price – MSH 2010); INN: 
international non-proprietary name. 
	  
Table 3. 7. Examples of price variations across private pharmacies for the same 
medicine (only LPGs). 
Medicine name and 
pharmaceutical form Minimum MPR Maximum MPR Ratio max/min 
Captopril 50mg tab 2.92 25.00 8.56 
Chloramphenicol 500mg tab 2.90 16.13 5.56 
Hydrochlorthiazide 25mg tab  6.76 54.05 8.00 
Metformin 500mg tab  4.76 23.81 5.00 
Omeprazole 20mg cap  2.78 16.67 6.00 
Ranitidine 150mg cap 2.50 12.50 5.00 
Simvastatin 20mg tab 5.11 34.92 6.83 
MPR: median price ratio; LPG: lowest price generic 
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The global results for our initial basket of 48 medicines are summarized in Table 
3.8. below.  
 
	  
Table 3. 8. Summary of medicine median price ratios (MPRs) for medicines for which 
≥4 prices were available. 
Median Price Ratio OB (n=6) LPG (n=25) 
Median MPR 47.09 8.33 
25%ile MPR 25.93 4.41 
75%ile MPR 103.10 12.82 
Minimum MPR 6.40 1.42 
Maximum MPR 186.05 36.84 
OB: originator brand; LPG: lowest price generic 
 
The price variations between originator brands and lower price generic 
equivalents were even more visible when MPRs for the originator brand and lower price 
generic equivalent were compared for the same medicine. The results of this paired 
analysis (which comprised only medicines for which both prices were found in at least 4 
outlets) is presented in Table 3.9. In the case of co-trimoxazole suspension for example, 
the originator brand’s price was more than 14 times higher than its lower price generic 
equivalent. 
 
 
Table 3. 9. Comparison between MPRs for originator brand a lower price generic 
equivalent of medicines for which ≥4 prices were available for both OB and LPG. 
Medicine name and 
pharmaceutical form OB (n=4) LPG (n=4) 
Atenolol 50mg tab 118.42 36.84 
Co-trimoxazole 8+40mg/ml susp 57.14 3.95 
Diclofenac 50mg tab 186.05 34.88 
Paracetamol 500mg tab 22.22 11.11 
OB: originator brand; LPG: lowest price generic 
 
Although prices tend to be higher in the sub-group of pharmacies located outside 
Dili (n=5), which buy their medicines mostly from the same importer/supplier in Dili, 
the global median MPRs for generic medicines do not seem substantially different when 
compared to the sub-group of pharmacies in Dili (n=16), showing only variations for 
minimum and maximum MPR values, as can be observed in Table 3.10. below. 
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Table 3. 10. Comparison of medicine MPRs for generic medicines for which ≥4 prices 
were available in private pharmacies in Dili and in the districts. 
Median Price Ratio Dili (n=16) Districts1 (n=5) 
Median MPR 8.33 8.45 
25%ile MPR 4.41 6.27 
75%ile MPR 11.90 11.62 
Minimum MPR 1.32 4.31 
Maximum MPR 34.88 22.22 
MPR: median price ratio 
1 Baucau (3 outlets), Bobonaro (1 outlet), Liquiçá (1 outlet) 
 
 
3.2.2. Public sector procurement prices 
As described before, the procurement of medicines for the public sector is 
(generally) done by SAMES, which is a semi-autonomous agency whose budget comes 
directly from the Ministry of Finance (government budget). In special cases, such as 
emergency purchases, the MoH can use a different procedure and sign contracts with 
authorized local suppliers.  
However, in some specific cases, the procurement is not handled by SAMES. 
Medicines for Malaria, TB and HIV/AIDS programs are procured through Global 
Fund’s procurement procedures (handled by the GF office in the country) and, likewise, 
contraceptives are procured via UNFPA, all from prequalified suppliers and all as 
originator brands. In our study, this is the case of 3 medicines: Coartem, Microgynon 
and Depo-Provera, which are therefore not included in the present analysis. 
The objective of this analysis was to compare SAMES and MoH purchase prices 
(from international and national suppliers) to international reference prices (IRP). Data 
collected refers to 3 contracts (2 from SAMES and 1 for an emergency supply from the 
MoH, all celebrated between June and August 2011), where one procurement price was 
obtained for 18 generic medicines included in our basket of 48. Like for patient price 
analysis, for procurement price analysis, prices were converted to a ratio of the 
International Reference Price (median price ratio or MPR), where a MPR > 1 indicates 
a purchase price higher than the IRP, whereas a MPR < 1 indicates that the medicine 
was procured at a price below the IRP.  
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For the 18 medicines included in our analysis (i.e. for which one price was 
obtained), the median procurement MPR was 1.06, showing a general alignment with 
international reference prices. However, a deeper analysis reveals values ranging from 
0.47 for hydralazine LPG and 3.65 for salbutamol inhaler LPG. The lowest MPR was 
for one medicine procured from an international supplier while the highest procurement 
MPR corresponded to a medicine purchased directly by the MoH from a national 
supplier. However, the data of just 3 procurement documents is not consistent enough to 
allow a more robust analysis of procurement prices and public procurement efficiency. 
Table 3.11. below summarizes the main findings of this section. 
 
Table 3. 11. Summary of medicine specific median price ratios (MPRs) for medicines 
with ≥1 procurement price available (all LPGs). 
Median Price Ratio LPG (n=18) Remarks 
Median MPR 1.06  
25%ile MPR 0.74  
75%ile MPR 1.85  
Minimum MPR 0.47 Hydralazine injection, international supplier 
Maximum MPR 3.65 Salbutamol inhaler, national supplier 
LPG: lowest price generic 
 
The calculations were made based on the prices CIF16 found in public sector 
procurement contracts with different suppliers. In addition, importers (be it SAMES or 
any private importer) pay an import duty of 2.5% and a sales tax of 2.5%, as specified 
in the Taxation Law (Law 08/2008). Under the same legislation, medicines are exempt 
of excise tax, applicable to other goods for sale. 
 
	    
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
16CIF: price includes cost, insurance and freight.  
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3.3. AFFORDABILITY OF TREATMENTS 
Since, as previously mentioned, medicines in the public sector are distributed 
free of charge to the population, the analysis of this parameter refers only to medicines 
purchased in the private sector. The affordability analysis is therefore based on the 
median prices obtained in private pharmacies for medicines used to treat common 
health conditions. 
In the present study, the affordability analysis follows the WHO/HAI 
methodology and is based on the salary of the lowest paid unskilled government worker. 
The methodology defines a course of treatment as unaffordable if it costs more than the 
equivalent to one day’s wages; treatments are considered affordable if they cost the 
equivalent to one day’s wages or less.  
The salary of the lowest paid government worker in Timor-Leste was, at the 
time of the study, 115 USD. This corresponds to a daily wage of 3.83 USD.  
Table 3.12. shows examples of treatment affordability for common conditions 
treated with some of the medicines surveyed. For some conditions, multiple treatment 
options are presented. In the case of acute conditions the usual course of treatment for 
one episode (in dose and number of days) was considered, while for chronic conditions 
the duration of treatment based on which calculations were made was one month.  
Treatment of acute infections with antibiotics was, in general, considered 
affordable (except in the case of systemic infection treatment with gentamicin injection), 
as well as the treatment of mild pain/fever in adults and children (0.2 for paracetamol 
suspension to 0.3 or 0.6 for paracetamol tablets LPG or OB, respectively). This 
reasoning is valid for one course of treatment of one single episode and not in case the 
illness episode is repeated and/or there is more than one family member in need for 
treatment. The use of oral or injectable contraceptives (0.5 day’s wages/cycle in both 
cases) was also considered affordable.  
The treatment of all other conditions presented in Table 3.12. is generally 
unaffordable, if the patient uses generic medicines. The treatment with the equivalent 
originator brand is at least twice as expensive (paracetamol tablets) up to almost 15 
times more expensive (co-trimoxazole suspension) than when using generics. The two 
treatment options considered in the present analysis for the treatment of diabetes 
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(glibenclamide and metformin) and the two treatment options for hypertension (atenolol 
and captopril), for example, are considered unaffordable according to our definition. 
 
 
Table 3. 12. Median expenditure (day’s wages) the lowest paid government worker 
would have to spend in medicines used to treat common conditions. 
Condition Medicine Treatment duration (days) OB LPG 
Asthma Salbutamol 100mcg/dose inhaler as needed  2.0 
Diabetes Glibenclamide 5mg tab 30  1.6 
Diabetes Metformin 500mg tab 30  2.9 
Hypertension Atenolol 50mg tab 30 8.8 2.7 
Hypertension Captopril 50mg tab 30  1.8 
Hypercholesterolemia Simvastatin 20mg tab 30  2.3 
Adult resp. infection Ciprofloxacin 500mg tab 7  0.5 
Adult resp. infection Amoxicillin 500mg tab 7  0.5 
Adult resp. infection Ceftriaxone 1g inj 1  0.7 
Paediatric resp. infection Co-trimoxazole 8+40mg/ml susp 7 4.4 0.3 
Arthritis Diclofenac 50mg tab 30 12.5 2.3 
Arthritis  Ibuprofen 400mg tab 30  2.3 
Pain/inflammation  Paracetamol 24mg/ml susp 3  0.2 
Pain/fever (mild) adults Paracetamol 500mg tab 3 0.6 0.3 
Ulcer/dyspepsia Omeprazol 20mg cap 30  2.0 
Ulcer/dyspepsia Ranitidine 150mg tab 30  2.3 
Contraception EE/LVG (COC) cycle 30 0.5  
Contraception  Medroxyprogesterone 150mg inj 30  0.5 
Topical fungal infection Clotrimazole 1% cream as needed 1.3  
Adult systemic infection Gentamicin 40mg/ml inj 7  11.0 
OB: originator brand; LPG: lowest price generic; EE/LVG (COC): ethinyloestradiol/levonorgestrel 
(combined oral contraceptive) 
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4. DISCUSSION AND CONCLUSIONS 
In the following section the factors that can limit access of the population of 
Timor-Leste to affordable pharmacological treatments (availability, prices and 
affordability) are discussed, exploring the limitations of the study and the possible 
interpretation of the findings from the survey. International comparisons were made 
with data from other surveys conducted throughout the world since 2008 (based on the 
methodology described in the manual’s 2nd edition) in low- and lower-middle-income 
countries.17 
 
4.1. KEY FINDINGS 
4.1.1. Availability of medicines 
Following WHO/HAI’s ranges for availability (< 30% very low; 30-49% low; 
50-80% fairly high; 80% high),(61) mean availability of generic medicines in the 
Timorese public sector can be considered comparatively acceptable, ranging from 52.3 
to 67.2% across the five districts surveyed. In contrast, originator brand availability is 
very low, which suggests that the government’s policy intended to favour generic 
medicines is being followed in public procurement processes. In fact, from the list of 
medicines surveyed in the present study, practically all OB medicines found in public 
outlets were medicines procured through funded programs (Global Fund for HIV/AIDS, 
malaria and TB and family planning vertical programs), which follow donor’s specific 
procurement guidelines and the public procurement agency (SAMES) is only 
responsible for medicines distribution. This preference for the use of generic medicines 
in public health services has been generally observed in recent surveys conducted in 
several low- and lower-middle-income countries (refer to Table 1.1. Chapter 1).  
Availability is higher in hospitals than in CHCs, which is not surprising if the 
distribution system is taken into account. At district level, regular distribution of 
medicines coming from SAMES is centralized in District Health Services; each sub-
district CHC then collects and transports medicines to their final destination (in a van 
allocated to the CHC). Because this transport depends on road and vehicle conditions, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
17 World Bank classification. Available from: http://data.worldbank.org/about/country-
classifications/country-and-lending-groups (accessed on 22 Jul 2012). 
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availability of medicines is usually lower in more remote locations, while hospitals and 
CHCs located in urban centres are favoured due to their location closer to SAMES 
warehouse (in the case of Dili) or district level storage facilities. Another reason which 
for higher availabilities found in Dili is that some of these CHCs receive donated 
medicines from NGOs with more activities in the capital (donations were not found at 
CHC level in any other districts). In one CHC in Dili, for example, donations also 
included equipment such as an air conditioning system, which clearly improved the 
pharmacy’s storage conditions.  
Given the fact that medicines are supplied to and within the districts mostly by 
road,18 availability in districts with better road conditions (Dili and Baucau) was 
generally above national average. These regional differences have been observed in 
previous studies in similar contexts,(31) although sometimes the link between 
availability and geographic location is weak and non-significant.(22) Nevertheless, 
these data seem to support the idea that investment is still necessary to improve the 
access of populations living in remote (and poorer) locations to medical treatments, and 
that this effort should focus also on infrastructures and logistic conditions in order to 
reduce geographic obstacles to access. 
When specific therapeutic groups are considered, availability is high for 
NSAIDs and fairly high for oral antibiotics and oral cardiovascular medicines, which 
reflect a rather good provision of some essential medicines to the population. In contrast, 
however, availability of selected medicines for maternal and children care remains 
below 50% in the public sector (both for OBs and LPGs). Reproductive health 
indicators remain an important challenge in Timor-Leste; for instance, lifetime risk of 
maternal death was found to be 1 in 35(62) and under-five mortality remains at 56 per 
1000 living births.(63) MNCH has been identified as a priority area for intervention in 
Timor-Leste;(64) however, these low availability results suggest that the government 
probably needs to give more emphasis to pharmaceuticals as a component of MNCH 
programs. 
Similarly to what has been observed for the public sector, availability of OBs in 
the private sector is also very low, despite considerable variations across the 21 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
18In the case of Oecussi, medicines are normally transported by boat to the district capital, Pante Makasar, 
and to the subdistricts by road. 
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pharmacies surveyed. As for generic medicines, however, while availability in the 
public sector is generally considered as fairly high (close to 60.0%), in private retail 
pharmacies it is generally low (less than 40.0%). No medicine from our list was 
consistently found in all the outlets surveyed in the private sector (in the public health 
facilities, in contrast, 6 medicines had a mean availability of 100%).   
In Timor-Leste, despite the limited budget for medicines,(51) the government 
has managed to maintain medicines availability in the public sector at reasonable levels, 
diminishing, to a certain extent, the role of the private sector in the provision of 
pharmaceuticals to the population. For instance, recent data show that 77% of oral 
contraceptives are obtained in public health facilities in Timor-Leste, and less than 14% 
from the private for profit sector.(65) 
Although most private pharmacies are concentrated in Dili, and district data was 
limited, it was still possible to observe marked regional differences: in the case of 
generics, pharmacies in Dili (n=16) show a mean availability which can be classified as 
low, while in pharmacies outside Dili (n=5) availability is very low, almost half when 
compared to Dili. The same pattern is observed for originator brands, although overall 
availability is very low for both types of medicines. The most likely explanation for this 
difference is that, as the supply chain for medicines in Timor–Leste does not include 
wholesalers or distributors, private pharmacies in the districts must get their supplies 
from Dili by their own means, traveling only when medicine stock levels become 
critically low. These observations indicate that if people with more financial resources 
living in Dili can still rely on some private pharmacies to buy medicines not found in 
the public healthcare facilities, outside Dili, the private system is hardly a viable 
alternative. 
When looking at the existing literature on medicines availability, prices and 
affordability the pattern described is normally one of low availability in the public 
sector (where medicines are free or sold at a lower price) forcing the population to 
purchase medicines from the private sector, more available, but at a higher cost.(8, 9, 
13) When we analyse Timor-Leste data, though, another pattern prevails: the public 
sector shows a higher availability than the private for most medicines considered. 
Timor-Leste is not an isolated case as this ‘opposite pattern’ has been found in 
some other countries (refer to Table 1.1. Chapter 1). Lower availabilities in the private 
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sector are generally seen in countries where the private sector is poorly regulated and 
the few existing regulations are not monitored. Data from these studies suggests that 
poor regulation in these contexts might be preventing the development of a strong 
private sector. 
While the pattern found in Timor-Leste has been observed in other countries in 
Southeast Asia region, Indonesia and Thailand, as well as in other world countries in 
comparable stages of development (Burkina Faso, Guatemala, São Tomé and 
Príncipe),(23) it is still interesting to see that Timor-Leste’s results are opposite to what 
is generally observed in countries where no fees apply to medicines in the public 
sector.(23)  
 
4.1.2. Private sector patient prices 
As previously pointed out, in the public sector medicines are distributed free of 
charge to the population and no fees apply to patients using public health facilities in 
Timor-Leste. Thus, patient price discussion only applies to the private sector. 
Contrarily to procurement prices, where a cut-off point of acceptable/non-
acceptable MPR is fairly easy to define, patient prices in retail pharmacies are a 
combination of the manufacturer’s selling price and additional costs resulting from the 
various steps of the supply chain, which add up to the final price. It is therefore difficult 
to draw a line between what can be considered as an acceptable selling price and what is 
excessive. A WHO/HAI comparison report on price, availability and affordability of 
medicines used the cut-off point of MPR ≤ 2.5% in order to facilitate discussion(61); 
this criterion has been adopted by other studies(31) and will be used in this analysis. 
Only one medicine from our list (for which at least 4 retail prices were found) 
showed a MPR lower than the 2.5 threshold – generic medroxiprogesterone 150 mg/ml 
injection. All other MPRs found for generic medicines can be considered high 
according to the above-mentioned criteria. Originator brands considered in this analysis 
were found to have MPRs 2-14 times higher than their generic equivalent, and were 
unacceptably expensive when compared to international standards. Price variations 
across private outlets were also substantial for some essential medicines – captopril 50 
mg tablets for example can be 8.5 times more expensive depending on the private 
pharmacy visited. These results clearly reflect the inexistence of government regulation 
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on retail prices and margins. Pharmacy prices even showed variations within the same 
outlet, whether medicines were purchased following a medical consultation held in the 
pharmacy’s premises or with another/no prescription; again, no regulation exists aimed 
at controlling this kind of practice.  
Our findings raise doubts on the effective role of private retail pharmacies in the 
Timorese health system, given the lower availability and higher prices of essential 
medicines when compared to the public sector. One explanation could be the far from 
ideal conditions of the public health facilities, generally overcrowded (and with limited 
working hours in case of CHCs), which can push some people to seek more expensive 
care in less crowded retail points in the private sector, where primary care and 
medicines can also be provided. Another explanation could be that the private sector is 
mainly serving certain sections of the population, with a larger level of income, who 
choose the private sector’s (slightly) better ancillary conditions. Nevertheless, these 
possible explanations only apply to Dili (and Baucau, to some extent), since the private 
sector in the rest of the country is practically inexistent. The private not-for-profit sector 
(NGOs for instance) might also have an important role in the provision of medicines in 
target intervention areas, constituting an alternative to both the NHS and private retail 
pharmacies. 
Additionally, some larger private pharmacies belong to local companies with 
license to import and supply medicines and other health commodities to the public 
sector (through the public procurement agency – SAMES – or the Ministry of Health) 
and other smaller private pharmacies. The retail business could therefore serve only as a 
secondary/complementary business for these companies who would get most of the 
profits from their activity as ‘wholesalers’.     
Prices in the private sector in Timor-Leste are among the highest found in recent 
surveys carried out in low- and lower-middle-income countries, regardless of the world 
region considered (refer to Table 1.2. Chapter 1). The situation in Timor-Leste is similar 
to what has been described in countries with higher patient prices in the private sector 
(like São Tomé and Príncipe and Haiti) do not have specific regulation on prices and 
margins or have some regulation but it is not efficiently monitored.(31,66) 
It is interesting to observe, though, that in Indonesia, the median MPR found for 
a basket generic medicines surveyed was relatively low. Since most medicines sold in 
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private retail pharmacies in Timor-Leste are imported from Indonesia, this suggests that 
either private importers are systematically not able to negotiate better prices with 
Indonesian suppliers (which could be due to the low amount of drugs imported) or that 
substantial margins are added locally by Timorese market players.   
Caution is necessary, however, when comparing prices across different countries 
and survey years, as price adjustments are necessary given the differences in medicines 
reference prices in different years, inflation rates and purchasing power of the local 
currency of countries considered.  
 
4.1.3. Public sector procurement prices 
Public procurement efficiency was evaluated by comparing MPRs of 
procurement documents with international reference prices.  
Public procurement data in Timor-Leste was obtained from three tender 
documents, two of which from a national supplier and one from an international 
supplier. From the medicines included in our list, one single price was found for 18 
different medicines, which considerably limits any discussion over this matter. 
Nevertheless, this limited information reveals a median MPR of 1.06, which according 
to WHO/HAI methodology reflects a fairly efficient procurement system (MPR ≤ 1 is 
considered efficient, meaning drugs are procured for prices which are equal or below 
IRP). Although data does not allow price comparison for the same medicine, if we 
analyse the international tender process (international contest) vs. locally procured 
medicines (procured using a request for quotations from pre-selected suppliers), some 
differences seem to arise: while MPR referring to medicines procured from the 
international supplier (n=4) range between 0.69 and 1.02 (and the process can be 
considered efficient), MPRs from the local supplier (n= 14) range between 0.47 and 
3.65, and for 9 out of 14 medicines MPRs are actually ≥ 1. Although limited, this brief 
analysis suggests that despite government’s recommendations to procure drugs through 
international tender processes, some drugs are being procured from pre-selected local 
importers (mostly in case of emergency supplies, due to stock-outs), at higher prices.    
Reports from other low- and lower-middle-income countries where this analysis 
was recently undertaken, show a similar procurement median MPRs for medicines 
procured by the public sector, except for Philippines and Indonesia (Table 5, Appendix 
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5). The fact that most local private importers use Indonesian medicines suppliers might 
be one of the reasons for the high prices observed in the private sector in Timor-Leste. 
As mentioned in the previous section, caution is necessary when interpreting 
unadjusted MPRs across multiple studies. 
 
4.1.4. Affordability of treatment 
Affordability analysis using the WHO/HAI standard methodology compares the 
costs of pharmacological treatments to the salary of the lowest paid unskilled 
government worker, based on the assumption that this reflects the country’s cost of 
living. (see below in Chapter 4.2.1. Limitations of the original WHO/HAI 
methodology). 
A course of treatment is considered affordable if medicines costs do not exceed 
the salary equivalent to one working day and unaffordable when it goes beyond this 
amount. However, according to the latest World Bank data, more than one third of the 
Timorese population lives below the 1.25 USD/day poverty line, which means that even 
treatments considered ‘affordable’ according to this methodology might not be truly 
affordable to many people. Nevertheless, this approach allows international 
comparisons with similar contexts, which can give a rough idea of the situation in 
Timor-Leste. 
While antibiotics, common painkillers and contraceptives are generally 
affordable as per the WHO/HAI standards, other medicines such as anti-hypertensives, 
NSAIDs, medicines to treat ulcer/dyspepsia and anti-diabetics generally cost more than 
one daily wage. These last two therapeutic groups are interesting to analyse, since 
contrarily to the general availability trend found in our study, the two anti-diabetics 
included in our list (glibenclamide and metformin) and one of the most common 
medicines used to treat peptic ulcer (omeprazol) showed a higher availability in the 
private sector when compared to the public sector. This may suggest that for specific 
medicines or therapeutic groups, private pharmacies may actually have an important 
role in the system, filling the low-availability gap in the public sector. Nevertheless, for 
most of the population these treatments remain not only unaffordable, but also 
inaccessible since this reasoning applies almost exclusively to Dili, where most private 
retail pharmacies are concentrated. Unaffordability of treatments with originator brands 
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is even more marked, and can represent more than the equivalent of 12 working days 
for the medicines considered in our study. However, the adherence to generic medicines 
in Timor-Leste seems quite high (as shown by the extremely low availability of 
originator brands in the market, which suggests a very low demand), so high prices of 
OBs are likely to represent a minor issue when compared to other problems in the sector. 
Looking at other countries in Southeast Asia where the same methodology was 
applied for medicines affordability analysis (India NCT and Indonesia), Timor-Leste is 
clearly the country where treatments purchased in the private sector (even when lowest 
price generics are available) were most inaccessible due to cost barriers. Results are, 
nonetheless, comparable to other similar low- and lower-middle-income countries 
analysed in recent surveys in Central and South America and Africa (Table 6, Appendix 
5).(23) Findings for specific therapeutic groups also seem consistent with previous 
individual and multi-country reports: antibiotics are generally more affordable for the 
population than treatments for chronic diseases such as hypertension, diabetes, asthma 
or peptic ulcer.(13) 
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4.2. LIMITATIONS 
4.2.1. Limitations of the original WHO/HAI methodology 
Caution is necessary when interpreting availability results in this type of survey, 
since results refer only to the day of observation and may not reflect availability over 
time. This type of analysis also does not take into account other dosage forms or 
possible alternative treatments for the same health condition. For instance in Timor-
Leste, ciprofloxacin in tablet form and 500 mg strength was systematically reported as 
unavailable in the public sector; however, is most facilities visited, 250 mg tablets of the 
same medicine were usually found as an alternative (but not considered as per 
WHO/HAI methodology).  
Additionally, the fact that one medicine is physically present in the healthcare 
facility (thus available), does not necessarily mean it has adequate quality. An 
appropriate storage and distribution system is necessary to ensure medicines safety, 
efficacy and quality according to internationally accepted standards.(67) By focusing 
only on physical availability, this important aspect affecting the access to adequate 
treatment is overlooked by the methodology.  
Affordability analysis also followed the methods described in the WHO/HAI 
manual, based on the salary of the lowest paid unskilled government worker. This kind 
of approach has been widely used in other studies (namely in studies that follow 
WHO/HAI’s procedures, for comparison purposes) as a measure of the financial impact 
medicines have on the population. Despite its simplicity and straightforwardness the 
application of this kind of approach (in the field of medicines as in other fields) has 
been criticised for not reflecting the real population’s ability to pay for medicines. In 
Timor-Leste the salary of the lowest paid government worker is set in 115 USD and 
calculations for the affordability of a standard treatment for several conditions were 
made based on that amount. However, the population of Timor-Leste working in public 
administration is only about 2.2%.19 On the other hand, latest available data from the 
WB (2007) places more than one third of the population (37.4%) below the poverty 
threshold of 1.25 USD/day. This means that in Timor-Leste, as well as in other similar 
countries, the majority of the population earns much less than the salary of the lowest 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
19Census 2010. Available from: http://dne.mof.gov.tl/ (accessed on 22 Jul 2012). 
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paid unskilled government worker. Additionally, an affordability analysis based solely 
on the price of medicines does not take into account other factors that affect the 
population’s ability to pay for medical treatments, or indirect costs, like private doctor 
fees and/or transport costs to healthcare facilities, which can be significant, particularly 
in a context where all private pharmacies are located in urban centres.  
 
4.2.2. Limitations of the present study 
The whole data collection task was undertaken by one investigator alone, and 
not by teams of two, as recommended in the manual; data collection forms were 
checked at the end of each working day by the same investigator. Although this can be 
seen as an advantage in terms of standardization of the data collection procedure, it can 
increase the probability of systematic errors.  
Limitations related to lack of transport or bad weather conditions limited the 
access to some geographic areas and/or health facilities; it was therefore impossible to 
fully comply with the sampling process recommended by WHO/HAI. However, given 
the small dimension and population of Timor-Leste, it was considered that the sample 
chosen for the public sector could still represent the country as a whole since facilities 
surveyed covered 44.1% of the country’s population, with a suitable balance between 
urban and rural population (52.5% and 47.5%, respectively). As for the private sector, 
the particular distribution pattern made the WHO/HAI sampling recommendations 
unfeasible. Nonetheless, almost 90% of all private retail outlets registered in the country 
at the time of the study (21 out of a total number of 24, if we exclude 2 already closed 
when the study started and 2 exclusively dedicated to Chinese medicines) were actually 
surveyed (16 out of 19 in Dili, and 5 out of 7 in the districts), which can probably be 
considered as representative of the private sector in the country.  
Given the above-mentioned limitations, a two-month period was necessary to 
complete the study. As medicines supplies are received by CHCs in the districts on a 
quarterly basis, some differences in the availabilities observed between the districts may 
have reflected this time gap. 
The WHO/HAI complements the analysis of procurement prices with a price 
components study. The objective of this analysis is to help clarify the impact of the 
various additional costs added to the medicine’s selling price along the supply chain 
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until they reach the final consumer; this information can be crucial when planning 
policies aimed at improving the price regulation in the pharmaceutical sector. However, 
given the sensitivity of the matter and lack of regulation in Timor-Leste (which can give 
rise to some not so transparent practices), pharmacy owners and other actors related to 
the pharmaceutical market were usually afraid or not willing to disclose this kind of 
information for the investigation. Therefore, we decided to exclude price component 
analysis, as per WHO/HAI standards, from our study, limiting our understanding on 
how the pharmaceutical market works in Timor-Leste and failing to give us some 
insight on how it might be improved as far as medicines prices are concerned. 
Finally, as price comparison between different countries requires more complex 
calculations, taking into account factors such as inflation rates and purchasing power of 
local currencies, no comparisons were made for individual medicines and caution is 
necessary when comparing general results for baskets or samples of medicines, with 
different compositions. International comparisons of availability and affordability are 
not affected by the factors described above and may be performed without further 
adjustment. 
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4.3. POLICY IMPLICATIONS OF STUDY FINDINGS 
Over the past 10 years, more than 50 surveys using the same standard 
methodology have been carried out in low- and middle-income countries, highlighting 
the importance of these parameters for the identification of the root causes of poor 
access to medicines. Scant evidence exists that governments have used results from 
these surveys as guidance to take action and develop policies aimed at improving the 
availability of essential medicines at affordable prices. However, it is hoped the findings 
from this study can be regarded as an opportunity to improve the pharmaceutical sector 
in Timor-Leste. 
Although a fairly high availability of essential medicines was found in the public 
sector, some improvements are still necessary in order to ensure access to (good-
quality) medicines to the population of Timor-Leste. Efforts have been made in recent 
years to update documents such as the essential medicines list (EML) and standard 
treatment guidelines (STG) for primary care. However, doctors working in the national 
health system (including many expatriates) are not fully aware of the utility of 
following these documents and there is some lack of coordination between available 
drugs (SAMES uses EML guidance for drug procurement) and prescription patterns. 
Large quantities of untouched medicines close to expiry date or expired were 
consistently found in the facilities visited. It is therefore necessary that the government 
takes action to improve the adequate dissemination of these documents within the 
system (which includes translation of English versions into the main working languages 
in Timor-Leste – Tetum, Portuguese and Indonesian) as well as to promote training of 
health professionals (doctors, nurses and pharmacy personnel) on rational use of 
medicines in order to improve the system’s performance and reduce drug waste, in line 
with what has been suggested in previous reports. A reduction in the number of 
medicines included in the current EML as well as a better stock monitoring system in 
the public health facilities might also contribute to improve the efficiency of the 
procurement system, avoiding the procurement of unnecessary drugs and insufficient 
amounts of the most commonly used drugs, leading to stock-outs.  
In Timor-Leste drug regulation is very patchy, and regulatory and monitoring 
responsibilities are not concentrated in one fully empowered regulatory authority, but 
scattered between various state-controlled entities (DOP and CRAF, but also SAMES in 
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the case of drug quality testing). As pointed out in a recent WHO report,(51) the 
government is currently evaluating a national drug policy but the draft version has not 
been approved by the parliament to date. Medicines policy, according to WHO, should 
have the following objectives: (i) the equitable availability and affordability of essential 
medicines; (ii) the quality, safety and efficacy of all medicines; and (iii) therapeutically 
sound and cost effective use of medicines by health professionals and consumers.(68) 
Many of these aspects are actually already covered in current legislation and guidance 
documents; however, as in many other low- and middle-income settings, 
implementation of existing policies has not been fully established. For instance, 
monitoring and inspection of activities and common practices in the private sector is 
very inefficient; this situation constitutes a public health issue (e.g. psychotropic 
medicines are imported and sold despite government’s recommendations, antibiotics are 
freely sold over the counter in many pharmacies), but offenders are seldom detected. It 
is therefore important that action is taken, not necessarily through the creation of new 
legislation, but starting by urgently reinforcing the existing one, and then incrementally 
move on to the other areas requiring the regulator’s attention. A drug policy 
implementation plan should clearly define the main activities to be undertaken, 
responsibilities for undertaking these activities, among the various departments and 
agencies involved, and estimate the resources that should be available in order to carry 
them out. The reduced number of human resources with adequate training limits the 
number of professionals that could be involved in pharmaceutical inspection and 
monitoring activities; this aspect seems nonetheless crucial at this stage and is still 
worth mentioning. 
Currently, profit margins applied to medicines in the private sector are not 
regulated. This is probably contributing to create an unfavourable environment for the 
private sector, since small businesses are unlikely to survive in a system where a few 
vertically integrated groups (importers with their own retail pharmacy) control market 
prices (and practices). Although it is known to increase efficiency in some cases, 
vertical integration can also limit competition and consumer protection.(69) Regulation 
on medicines prices, like the establishment of maximum margins, could be useful not 
only to make them more affordable to the population but also as a mechanism to favour 
the development of the private sector.  
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As the private sector develops, established businesses groups become 
increasingly dominant, influencing regulation favouring their vested interests.(69) Since 
the private sector in Timor-Leste is still emerging, this is probably the most appropriate 
moment for the government to consider the development and reinforcement of legal 
mechanisms before they become harder to implement. 
Another possible topic of discussion could be the long-term sustainability of a 
publicly funded pharmaceutical system. Although availability of drugs surveyed in the 
present study was considered reasonable, insufficient funds for the procurement of 
drugs have been identified as one of the main reasons for stock-outs at SAMES. Some 
countries facing the same problem have introduced user fees in order to help financing 
the public system – user fees can be re-invested in the health system to improve the 
quality of services provided, for instance, the availability of medicines.(12) Although 
the success of user fees implementation is not consensual,(70) a debate over the 
sustainability of the public health system should be considered by the Timorese 
authorities, particularly given the population growth rate observed in the country and 
the intention to expand the health services to serve more remote communities. 
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4.4. FUTURE AREAS OF RESEARCH 
As described in the study limitations, the survey conducted in Timor-Leste 
focused only on availability and prices of medicines and did not explore the price 
components as per WHO/HAI’s methodology. It would therefore be useful to 
complement the present availability and price survey with a study focussing on price 
components and margins applied by the various market players, with the objective to 
provide policy-makers with firm evidence on what drives the sector’s performance. 
Additionally, it would be interesting to look more deeply at the private sector consumer 
profile (vs. public) to gain a better understanding of the role the private retail 
pharmacies may have in the Timorese health system. 
In the present study, drug availability was measured using a list of 48 medicines 
covering several therapeutic/intervention areas. However, one problem identified 
throughout the survey in the public sector was that some drugs, although available, were 
seldom prescribed by doctors working in the health facility and remained in the shelves 
untouched until expired. Although there have been some efforts to update the national 
essential medicines list and standard treatment guidelines, a gap is still apparent 
between procurement options and real needs. The rational use of medicines is not a new 
issue and has been addressed before in Timor-Leste, but an updated comprehensive 
study on the adherence to the national EML and most recent STGs complemented by 
the evaluation of prescription patterns should also deserve some attention in future 
research given the limited resources for medicines in the public sector. 
As pointed out in the introduction section, availability of (good-quality) essential 
medicines depends on an efficient supply system, which includes factors such as the 
selection, procurement and distribution of drugs.  The adequate distribution of drugs in 
turn, depends on factors such as transport and storage conditions. In some of the 
facilities visited storage conditions are far from ideal (high temperatures with no air 
conditioning system, no plague control, open-air storage, no segregation of expired 
items), which can critically affect the final quality of medicines provided to the 
population. Even though this type of study would be likely to involve considerable 
resources, it would be useful to analyse the real quality of drugs supplied by the public 
health system, since this can seriously affect the efficacy and safety of treatment 
provided. 
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Finally, the approach used to measure affordability in the present study, based 
exclusively on medicines prices, has several limitations. Not only the salary of the 
lowest paid government worker is not representative of the monthly income of most of 
the population, but it also does not take into account indirect costs that families have to 
face in order to receive the medicines they need. Even when medicines are dispensed 
free of charge by the national health system, transport to the closest healthcare facility 
in remote locations for example, may represent a cost beyond people’s reach. It would 
therefore be interesting to evaluate the impact of other costs related to treatment in order 
to have a better idea of real affordability of obtaining pharmacological treatment in 
Timor-Leste. 
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4.5. CONCLUSIONS 
Over the past 10 years, more than 50 surveys using the same standard 
methodology developed by HAI and WHO have been carried out in low- and middle-
income countries, highlighting the importance of these parameters for the identification 
of the root causes of poor access to medicines. To date, no study had been conducted to 
describe the availability, prices and affordability of medicines in Timor-Leste; however, 
comparable issues have been identified in Southeast Asian countries and other countries 
in similar stages of development. Taking stock of the country’s situation was therefore 
considered of great utility and provide a basis for subsequent studies, recommendations 
and interventions. 
Between November 2011 and January 2012 a survey was conducted in five 
districts of Timor-Leste using the WHO/HAI methodology, adapted to the Timorese 
context. In the public health system, mean availability of a selected list of essential 
medicines was 59.6% for generics and 7.3% for branded medicines; in private retail 
pharmacies mean availability was even lower for generics (38.0%), and comparable 
(9.2%) for originator brands. Prices of medicines in the private sector can go up to 186 
times their international reference prices, in case of brands and to 35 times more in case 
of generics, respectively. In a country where still more than one third of the population 
lives with less than 1.25 USD/day, this translates into some pharmacological treatments 
being unaffordable to a large section of the population. Additionally to high prices, 
some other issues affecting medicines quality were also detected during the study, 
which further contribute to compromise the access of the Timorese population to 
adequate treatment. 
In some countries, governments have used results from these surveys as 
guidance to take action and develop policies aimed at improving the availability of 
essential medicines at affordable prices. Accurate information is essential for 
identifying the sources of poor access to pharmacological treatments and for planning 
any potential actions to address these issues. We hope this first description of the 
country’s situation and the results obtained in the present study will be useful and lay 
basis to subsequent studies and/or government interventions to better regulate the 
pharmaceutical sector, improving the public health system’s drug supply and quality, 
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and encouraging the growth of the private sector as a viable, affordable and safe 
alternative.   
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APPENDIX 1. SAMPLE SURVEYED 
 
Table 1. Public healthcare facilities surveyed, per district (n=22).  
District Hospital (district) 
Community Health Centre 
(sub-district) 
Dili (n=5) Guido Valadares National Hospital 
Cristo-Rei (Becora) 
Dom Aleixo (Comoro) 
Na’in Feto (Formosa)# 
Vera-Cruz (Bairro Pite) 
Baucau (n=5) Baucau Hospital 
Laga 
Vemasse 
Venilale 
Wailili 
Bobonaro (n=5) Maliana Hospital 
Atabae 
Balibo 
Bobonaro 
Maliana 
Covalima (n=3) Suai Hospital Suai Villa Zumalai 
Oecussi (n=4) Oecussi Hospital 
Bacqui 
Oesilo 
Passabe 
 #Pilot study. 
 
Table 2. Private retail pharmacies surveyed, per district (n=22).  
District Pharmacy 
Baucau (n=3) Bonita B Farmacia 
 Kabitan Farmacia 
 Samea Farmacia 
Bobonaro (n=1) Ainara Farmacia (Maliana) 
Dili (n=16) Baratu Farmacia 
 Bidau Farmacia 
 Bonita A Farmacia 
 Cini Farmacia 
 Citu A Farmacia 
 Citu B Farmacia 
 Centro Farmacia 
 Delmi Farmacia 
 Flodova Farmacia 
 Foho Osan Mean Farmacia 
 Forte Farmacia 
 Istana Farmacia 
 Moris Foun Farmacia# 
 Mother of Perpetual Help Farmacia 
 Murak Medic Farmacia 
 Prima Medica Farmacia 
Liquiçá (n=1) Primeiro Socorro Farmacia 
#Pilot study. 
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APPENDIX 2. MEDICINES SURVEYED 
 
Table 3. List of medicines surveyed, therapeutic category and international reference price (n=48).  
No. Medicine (INN) Strength Pharm. form Therapeutic category List IRP (MSH 2010) 
1 Acetylsalycilic acid 300 mg cap/tab Antithrombotic agents Supplementary $0.0027 
2 Amitriptyline 25 mg cap/tab Psychotherapeutic medicines Global $0.0076 
3 Amoxicillin 500 mg cap/tab Antibacterials Global $0.0290 
4 Ampicilin 1 g/vial vial Antibacterials Supplementary $0.1659 
5 Artemether/lumefantrine 20+120 mg cap/tab Antimalarials Supplementary $0.1000 
6 Artesunate 50 mg cap/tab Antimalarials Supplementary $0.1667 
7 Atenolol 50 mg cap/tab Antihypertensives Global $0.0095 
8 Beclometasone (inhaler) 250 mcg/dose dose Antiasthmatic and drugs for COPD Regional $0.0170 
9 Benzathine benzylpenicillin 2.4 MIU vial Antibacterials Supplementary $0.2457 
10 Calcium gluconate (injection) 100 mg/ml millilitre Water, electroyte and acid-base balance Supplementary $0.0218 
11 Captopril 25 mg cap/tab Antihypertensives Global $0.0120 
12 Cefixime 400 mg cap/tab Antibacterials Supplementary $0.2960 
13 Ceftriaxone 1 g/vial vial Antibacterials Global $0.6900 
14 Chloramphenicol (injection) 1 g/vial vial Antibacterials Supplementary $0.3614 
15 Chloramphenicol (tablets) 250 mg cap/tab Antibacterials Supplementary $0.0155 
16 Ciprofloxacin 500 mg cap/tab Antibacterials Global $0.0306 
17 Clotrimazole (topical cream) 1% gram Antifungals for topical use Regional $0.0135 
18 Co-trimoxazole (suspension) 8+40 mg/ml millilitre Antibacterials Global $0.0042 
19 Co-trimoxazole (tablets) 480 mg cap/tab Antibacterials Supplementary $0.0106 
20 Diazepam 5 mg cap/tab Psychotherapeutic medicines Global $0.0061 
21 Diclofenac 50 mg cap/tab Non-opioid analgesics and NSAIDs Global $0.0043 
22 Doxycycline 100 mg cap/tab Antibacterials Regional $0.0117 
23 Enalapril 5 mg cap/tab Antihypertensives Supplementary $0.0102 
24 Ethinyloestradiol/levonorgestrel 30+150 mcg cycle Hormonal contraceptives Supplementary $0.3125 
25 Ferrum sulphate 60 mg Fe eq cap/tab Antianemic preparations Supplementary $0.0023 
26 Folic acid + ferrum sulphate 400 mcg + 60 mg cap/tab Antianemic preparations Supplementary $0.0026 
	  
74	  
27 Gentamicin (injection) 40 mg/ml millilitre Antibacterials Supplementary $0.0446 
28 Glibenclamide 5 mg cap/tab Antidiabetic agentes Global $0.0034 
29 Hydralazine (injection) 20 mg/ml millilitre Antihypertensives Supplementary $1.8720 
30 Hydrochlorothiazide 25 mg cap/tab Antihypertensives Supplementary $0.0037 
31 Ibuprofen 400 mg cap/tab Non-opioid analgesics and NSAIDs Regional $0.0094 
32 Magnesium sulphate (injection) 500 mg/ml millilitre Anticonvulsants Supplementary $0.0956 
33 Medroxyprogesterone acetate 150 mg/ml vial Hormonal contraceptives Supplementary $1.2297 
34 Metformin 500 mg cap/tab Antidiabetic agentes Regional $0.0105 
35 Metronidazole (injection) 5 mg/ml millilitre Antibacterials Supplementary $0.0040 
36 Metronidazole (tablets) 250 mg cap/tab Antibacterials Supplementary $0.0052 
37 Misoprostol 200 mcg cap/tab Oxytocics (MNCH) Supplementary $0.4481 
38 Omeprazole 20 mg cap/tab Antiacids and other antiulcer medicines Global $0.0300 
39 Oral rehydration salts (ORS) sachet for 1 L sachet Water, electroyte and acid-base balance Supplementary $0.0858 
40 Oxytocin 10 IU/ml millilitre Oxytocics (MNCH) Supplementary $0.1810 
41 Paracetamol (suspension) 24 mg/ml millilitre Non-opioid analgesics and NSAIDs Global $0.0039 
42 Paracetamol (tablets) 500 mg cap/tab Non-opioid analgesics and NSAIDs Supplementary $0.0045 
43 Ranitidine 150 mg cap/tab Antiacids and other antiulcer medicines Regional $0.0200 
44 Ringer's lactate IV solution millilitre Water, electroyte and acid-base balance Supplementary $0.0009 
45 Salbutamol (inhaler) 100 mcg/dose dose Antiasthmatic and drugs for COPD Global $0.0085 
46 Simvastatin 20 mg cap/tab Lipid lowering agents Global $0.0587 
47 Tetanus toxoid vaccine  vial Vaccines Supplementary $0.0872 
48 Vitamin A 100.000 IU (30 mg) cap/tab Vitamins and minerals Supplementary $0.0200 
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APPENDIX 3. DATA COLLECTION FORM 
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APPENDIX 4. MEDICINES PER THERAPEUTIC GROUP 
 
Table 4. Medicines, per therapeutic group and WHO/HAI list (availability analysis). 
Therapeutic  
group Medicine 
Therapeutic 
group Medicine 
Oral 
antibiotics 
Amoxicillin Cardiovascular 
disease   
(oral therapy) 
Acetylsalycilic acid  
Cefixime Atenolol 
Chloramphenicol tablets Captopril 
Ciprofloxacin Enalapril 
Co-trimoxazole tablets Hydrochlorothiazide  
Co-trimoxazole susp. Simvastatin 
Doxycycline   
Metronidazole tablets Regional SEAR 
(WHO/HAI) 
Beclometasone inhaler 
  Clotrimazole topical cream 
MNCH Ampicilin injection Doxycycline 
 Artesunate Ibuprofen 
 Benz. benzylpenicillin injection Metformin 
 Calcium gluconate injection Ranitidine 
 Cefixime Glibenclamide 
 Ethinyloestradiol/levonorgestrel  Hydralazine 
 Gentamicin injection   
 Magnesium sulphate injection Global 
(WHO/HAI) 
Amitriptyline 
 Medroxyprogesterone injection Amoxicillin 
 Metronidazole injection Atenolol 
 Misoprostol Captopril 
 Oral rehydration salts (ORS) Ceftriaxone injection 
 Oxytocin injection Ciprofloxacin 
 Ringer's lactate Co-trimoxazole susp. 
  Diazepam 
NSAIDs Diclofenac Diclofenac 
 Ibuprofen Glibenclamide 
 Paracetamol susp. Omeprazole 
 Paracetamol tablets Paracetamol tablets 
 Diclofenac  Salbutamol inhaler 
  Simvastatin 
MNCH: maternal, newborn and child health; NSAIDs: non-steroid anti-inflammatory drugs 
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APPENDIX 5. RESULTS FROM OTHER SURVEYS 
	  
Table 5. Public procurement prices in Timor-Leste and other low- and lower-middle-
income countries recently surveyed. 
 
Country 
Median Price Ratio – Public sector procurement prices 
(LPG) 
Orders Medicines Median MPR Min MPR Max MPR 
Timor-Leste 1 18 1.06 0.47 3.65 
India (NCT state) (2011) 5 44 0.59 0.08 3.44 
Indonesia (2010) 22 36 1.34 0.37 8.67 
Philippines (2008) 19 39 2.93 0.87 40.79 
Burkina Faso (2009) 1 44 1.13 0.27 4.90 
S. Tomé and Príncipe (2008) 1 45  1.02 0.14 10.42 
Nicaragua (2008) 1 36 0.95 0.15 20.52 
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Table 6. Affordability of treatments for some common conditions in Timor-Leste and other low- and lower-middle-income countries, 
recently surveyed. 
 
Condition Medicine Timor-Leste 
India 
(NCT state) Indonesia 
Burkina 
Faso 
São Tomé and 
Príncipe Haiti Guatemala Bolivia Nicaragua 
Asthma Salbutamol 100mcg inhaler 2.0 – – 1.2 – 0.8 1.3 1.6 1.8 
Diabetes Glibenclamide 5mg tab 1.6 – 0.2 0.6 6.6 0.8 – 1.1 0.8 
Diabetes Metformin 500mg tab 2.9 0.4 0.5 – – – – – – 
Hypertension Atenolol 50mg tab 2.7 0.4 – 2.5 4.1 0.9 – 1.1 0.6 
Hypertension Captopril 50mg tab 1.8 1.1 0.3 4.5 9.9 1.5 –  1.5 
Hypercholesterolemia Simvastatin 20mg tab 2.3 0.6 0.6 9.7 – 2.1 – – 5.9 
Adult resp. infection Ciprofloxacin 500mg tab 0.5 0.3 0.2 0.7 38.6 0.4 – 0.7 1.2 
Adult resp. infection Amoxicillin 500mg tab 0.5 0.8 0.3 1.0 2.3 0.5 – 0.8 0.7 
Paediatric resp. 
infection 
Co-trimoxazole 
8+40mg/ml susp 0.3 0.1 0.1 0.6 1.9 0.3 0.8 0.4 0.4 
Arthritis Diclofenac 50mg tab 2.3 0.4 0.5 0.7 19.8 1.3 – 0.8 1.0 
Pain/inflammation Paracetamol 24mg/ml susp 0.2 0.1 0.1 0.2 2.0 0.2 0.5 0.4 0.2 
Ulcer/dyspepsia Omeprazol 20mg cap 2.0 0.5 0.5 1.4 41.3 0.8 – 1.6 – 
Ulcer/dyspepsia Ranitidine 150mg tab 2.3 – 0.4 – – – – – 2.7 
Note: numbers in bold represent unaffordable courses of treatment (i.e. ≥ 1 day’s wages of the lowest paid unskilled government worker).
